## metadata
source file: data/floodlamp/reg/fda-townhalls/f5_fixnames/run_auto/2021-03-24_Virtual Town Hall 48_fixnames.md
last updated: 2025-01-03 Created QA Sections
link pdf: https://www.fda.gov/media/147211/download?attachment
link youtube: https://youtu.be/6crM00c06jg
link slides: 
topic: COVID-19


## content

### qa


#### 1. FDA Guidance on SARS-CoV-2 Testing and Validation.

QA Block 1-1
CLARIFIED QUESTION: Is pooling considered screening or surveillance when collecting a ten-swab pool where all the swabs are placed into the same transport tube with media and specimens are recollected for individual results?
CLARIFIED ANSWER: Pooling is considered screening if specimen collection results in determining the COVID-19 status of individual participants for actions based on those results.
VERBATIM QUESTION: Is pooling considered screening or surveillance when collecting a ten-swab pool where all the swabs are placed into the same transport tube with media and specimens are recollected for individual results?
VERBATIM ANSWER: This is regarding the use of pooling and in what situations that is considered screening versus surveillance. We have gotten a number of questions about surveillance versus screening and it is a tricky topic. So we did clarify with this specific situation that was asking about collecting a ten-swab pool where all the swabs are placed into the same transport tube with media. With the assumption that you plan to recollect specimens from each of those individuals if the pool is positive, where the intent is to determine each individual's COVID-19 status for SARS-CoV-2 positive or negative status -- such that that individual could or would take action based on that result. So in that case the testing protocol that was proposed appears to be screening since it is intended for individual action.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Pooling and screening, Surveillance testing, COVID-19 diagnostic protocols
REVIEW FLAG: False

QA Block 1-2
CLARIFIED QUESTION: Can you send questions about surveillance by email for specific feedback?
CLARIFIED ANSWER: FDA requests that specific questions about surveillance be sent by email to ensure detailed feedback tailored to the inquiry.
VERBATIM QUESTION: Can you send questions about surveillance by email for specific feedback?
VERBATIM ANSWER: What I would like to ask is that anyone who is interested in or has specific questions about surveillance, please send those in by email. We receive a lot of questions about testing proposals that are actually screening, not surveillance. And so we want to make sure that we have all the pertinent details before we give you feedback so that we can make sure that we provide the appropriate feedback for your specific situation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Surveillance inquiries through email, Feedback clarification
REVIEW FLAG: False

QA Block 1-3
CLARIFIED QUESTION: What are the recommendations for validating asymptomatic screenings when there is already an EUA for the qualitative detection of SARS-CoV-2?
CLARIFIED ANSWER: FDA recommends following the main molecular EUA template for individual asymptomatic screening claims. For serial screening claims, as per the supplemental EUA template, pre-authorization data is likely not needed. A supplemental EUA request should be submitted with the proposed serial testing interval and post-authorization validation study.
VERBATIM QUESTION: What are the recommendations for validating asymptomatic screenings when there is already an EUA for the qualitative detection of SARS-CoV-2?
VERBATIM ANSWER: Our recommendation generally for validating asymptomatic screening are included in the main molecular EUA template if you are interested in an individual screening claim. If you are interested in the serial screening claim as outlined in the supplemental EUA template, you likely don't need any additional pre-authorization data. In that case we recommend that you submit a supplemental EUA request with your requested indication including the serial testing interval and your proposed post authorization validation study.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA validation for screening, asymptomatic screening, serial screening claims
REVIEW FLAG: False

QA Block 1-4
CLARIFIED QUESTION: Do you need additional pre-authorization data for a serial screening claim outlined in the supplemental EUA template?
CLARIFIED ANSWER: The FDA suggests that additional pre-authorization data is likely unnecessary for a serial screening claim based on the supplemental EUA template. They recommend submitting a supplemental EUA request specifying the testing interval and the post-authorization validation study.
VERBATIM QUESTION: Do you need additional pre-authorization data for a serial screening claim outlined in the supplemental EUA template?
VERBATIM ANSWER: If you are interested in the serial screening claim as outlined in the supplemental EUA template, you likely don't need any additional pre-authorization data. In that case we recommend that you submit a supplemental EUA request with your requested indication including the serial testing interval and your proposed post authorization validation study.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: serial screening claim, EUA template, pre-authorization data
REVIEW FLAG: False

QA Block 1-5
CLARIFIED QUESTION: What data should be submitted for a supplemental EUA request including serial testing intervals and post-authorization validation studies?
CLARIFIED ANSWER: For a supplemental EUA request for serial screening, include your requested indication, serial testing interval, and proposed post-authorization validation study. Pre-authorization data is generally not needed if following the supplemental EUA template.
VERBATIM QUESTION: What data should be submitted for a supplemental EUA request including serial testing intervals and post-authorization validation studies?
VERBATIM ANSWER: So our recommendation generally for validating asymptomatic screening are included in the main molecular EUA template if you are interested in an individual screening claim. If you are interested in the serial screening claim as outlined in the supplemental EUA template, you likely don't need any additional pre-authorization data. In that case we recommend that you submit a supplemental EUA request with your requested indication including the serial testing interval and your proposed post authorization validation study.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Supplemental EUA request, Serial testing intervals, Validation studies
REVIEW FLAG: False

QA Block 1-6
CLARIFIED QUESTION: Is the serial testing approach acceptable for antigen assays that do not reach 80% sensitivity in symptomatic individuals?
CLARIFIED ANSWER: Serial testing may be supported for antigen tests with sensitivity under 80%, but clinical evaluation in asymptomatic populations must be completed before screening claims can be authorized. Post-authorization validation shifts are not allowed for tests below 80% sensitivity.
VERBATIM QUESTION: Is the serial testing approach acceptable for antigen assays that do not reach 80% sensitivity in symptomatic individuals?
VERBATIM ANSWER: We do discuss in the antigen template for test developers that strategies for serial testing with less sensitive tests such as the PPO less than 80% may be able to support authorization. But in those cases we would expect the clinical evaluation in an asymptomatic population to be completed prior to authorization of a screening claim. The shift of the validation to post authorization discussed in the supplemental template is not applicable for tests with sensitivity below 80% in symptomatic subjects.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: serial testing, antigen test sensitivity, EUA authorization
REVIEW FLAG: False

QA Block 1-7
CLARIFIED QUESTION: Should clinical evaluations in asymptomatic populations be completed prior to authorization for screening claims of tests with sensitivity below 80%?
CLARIFIED ANSWER: Clinical evaluations in asymptomatic populations must be completed before seeking authorization for screening claims of tests with sensitivity below 80%. Post-authorization validation is not applicable in such cases.
VERBATIM QUESTION: Should clinical evaluations in asymptomatic populations be completed prior to authorization for screening claims of tests with sensitivity below 80%?
VERBATIM ANSWER: We do discuss in the antigen template for test developers that strategies for serial testing with less sensitive tests such as the PPO less than 80% may be able to support authorization. But in those cases we would expect the clinical evaluation in an asymptomatic population to be completed prior to authorization of a screening claim. The shift of the validation to post authorization discussed in the supplemental template is not applicable for tests with sensitivity below 80% in symptomatic subjects.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Test sensitivity and screening, Clinical evaluations, FDA authorization requirements
REVIEW FLAG: False

QA Block 1-8
CLARIFIED QUESTION: What are the details required for the FDA to distinguish between a screening versus surveillance testing proposal?
CLARIFIED ANSWER: The FDA considers a testing protocol to be screening if its intent is to determine an individual's COVID-19 status for actionable purposes, such as recollecting specimens if a pooled test is positive. Proposals often considered as surveillance could actually be screening, so all pertinent details should be submitted by email for accurate feedback.
VERBATIM QUESTION: What are the details required for the FDA to distinguish between a screening versus surveillance testing proposal?
VERBATIM ANSWER: We have gotten a number of questions about surveillance versus screening and it is a tricky topic. So we did clarify with this specific situation that was asking about collecting a ten-swab pool where all the swabs are placed into the same transport tube with media. With the assumption that you plan to recollect specimens from each of those individuals if the pool is positive, where the intent is to determine each individual's COVID-19 status for SARS-CoV-2 positive or negative status -- such that that individual could or would take action based on that result. So in that case the testing protocol that was proposed appears to be screening since it is intended for individual action. Along those same lines we received over email one other question related to use of an EUA to test for surveillance purposes. And what I would like to ask is that anyone who is interested in or has specific questions about surveillance, please send those in by email. We receive a lot of questions about testing proposals that are actually screening, not surveillance. And so we want to make sure that we have all the pertinent details before we give you feedback so that we can make sure that we provide the appropriate feedback for your specific situation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: screening vs. surveillance testing, submission requirements
REVIEW FLAG: False

QA Block 1-9
CLARIFIED QUESTION: Under what circumstances is pooling considered screening rather than surveillance?
CLARIFIED ANSWER: Pooling is considered screening when the intent of the protocol is to determine each individual's COVID-19 status and to enable individuals to take action based on the result.
VERBATIM QUESTION: Under what circumstances is pooling considered screening rather than surveillance?
VERBATIM ANSWER: This is regarding the use of pooling and in what situations that is considered screening versus surveillance. We have gotten a number of questions about surveillance versus screening and it is a tricky topic. So we did clarify with this specific situation that was asking about collecting a ten-swab pool where all the swabs are placed into the same transport tube with media. With the assumption that you plan to recollect specimens from each of those individuals if the pool is positive, where the intent is to determine each individual's COVID-19 status for SARS-CoV-2 positive or negative status -- such that that individual could or would take action based on that result. So in that case the testing protocol that was proposed appears to be screening since it is intended for individual action.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Pooling, Screening vs Surveillance, COVID-19 Diagnostics
REVIEW FLAG: False

QA Block 1-11
CLARIFIED QUESTION: If a diagnostic test does not meet 80% sensitivity in symptomatic individuals, what are the requirements for FDA authorization of serial testing based on asymptomatic evaluations?
CLARIFIED ANSWER: For tests with sensitivity below 80% in symptomatic individuals, FDA requires a clinical evaluation in an asymptomatic population to be completed before authorizing a screening claim. Post-authorization validation is not applicable for these tests.
VERBATIM QUESTION: If a diagnostic test does not meet 80% sensitivity in symptomatic individuals, what are the requirements for FDA authorization of serial testing based on asymptomatic evaluations?
VERBATIM ANSWER: We do discuss in the antigen template for test developers that strategies for serial testing with less sensitive tests such as the PPO less than 80% may be able to support authorization. But in those cases we would expect the clinical evaluation in an asymptomatic population to be completed prior to authorization of a screening claim. The shift of the validation to post authorization discussed in the supplemental template is not applicable for tests with sensitivity below 80% in symptomatic subjects.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Serial testing, Clinical validation, FDA authorization
REVIEW FLAG: False

QA Block 1-13
CLARIFIED QUESTION: Are there specific details or formats required for pre-submission emails regarding surveillance testing?
CLARIFIED ANSWER: The FDA requests all pertinent details related to surveillance testing proposals in pre-submission emails to ensure accurate and appropriate feedback.
VERBATIM QUESTION: Are there specific details or formats required for pre-submission emails regarding surveillance testing?
VERBATIM ANSWER: We receive a lot of questions about testing proposals that are actually screening, not surveillance. And so we want to make sure that we have all the pertinent details before we give you feedback so that we can make sure that we provide the appropriate feedback for your specific situation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: pre-submission emails, surveillance testing, FDA feedback
REVIEW FLAG: False


#### 2. EUA Submission Process and Data Guidelines for Diagnostic Tests

QA Block 2-1
CLARIFIED QUESTION: What is the process for submitting data to OIR for an EUA?
CLARIFIED ANSWER: The FDA provides EUA templates for serology, antigen, and molecular tests on its website, and requests submission to cdrh-eua-templates@fda.hhs.gov. Submitted data is reviewed for sufficiency, and if supported, the FDA issues authorization and adds the test to its landing page.
VERBATIM QUESTION: What is the process for submitting data to OIR for an EUA?
VERBATIM ANSWER: We do have the EUA templates for serology, antigen and molecular test up on our Web site and ask that you submit your EUA request to cdrh-eua-templates@fda.hhs.gov. Those templates generally reflect our current thinking on the data and information that developers should submit to facilitate the EUA review process. Once we receive that we review your EUA request and determine whether it is sufficient to support an EUA authorization. And then at that point if we do believe it's sufficient, we would authorize the test then issue the sponsor letter of authorization and add that test to the FDA landing page.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submission process, Templates for diagnostic tests, FDA authorization workflow
REVIEW FLAG: False

QA Block 2-2
CLARIFIED QUESTION: For an OTC antigen test, is it necessary for the data to show a minimum of 80% agreement with a predicate to be considered for EUA approval?
CLARIFIED ANSWER: The FDA clarified that EUA reviews do not involve predicates as substantial equivalence determinations are not applicable. For OTC antigen tests, a minimum of 90% PPA compared to a comparator test is recommended, while 80% PPA is recommended for serial testing claims in symptomatic individuals.
VERBATIM QUESTION: For an OTC antigen test, is it necessary for the data to show a minimum of 80% agreement with a predicate to be considered for EUA approval?
VERBATIM ANSWER: So just to clarify some terminology there, for an EUA review, it is different than a 510k review. So for an EUA, it is not a substantial equivalence determination so there is no predicate. But we do often, you know, ask for a comparator test to be used in your clinical evaluation so I think that's likely what this question is referring to. And we do recommend for OTC tests in the antigen the - sorry, the non-lab template, we do recommend a minimum of 90% PPA for OTC tests as compared to the comparator test. And in the new supplemental template issued last week we recommend a minimum of 80% PPA for serial testing claims.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA requirements for OTC tests, Predicate vs comparator tests, Performance thresholds
REVIEW FLAG: False

QA Block 2-4
CLARIFIED QUESTION: What PPA do you recommend for serial testing claims in the new supplemental template issued last week?
CLARIFIED ANSWER: The FDA recommends a minimum of 80% PPA for serial testing claims, as indicated in the new supplemental template issued last week.
VERBATIM QUESTION: What PPA do you recommend for serial testing claims in the new supplemental template issued last week?
VERBATIM ANSWER: And in the new supplemental template issued last week we recommend a minimum of 80% PPA for serial testing claims.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: serial testing claims, PPA requirements, FDA supplemental template
REVIEW FLAG: False

QA Block 2-5
CLARIFIED QUESTION: Are the recommended PPAs for antigen tests applicable to symptomatic individuals?
CLARIFIED ANSWER: The FDA confirms that the recommended PPAs for antigen tests are applicable to symptomatic individuals. Comparator tests can include recently granted molecular tests or EUA-authorized high-sensitivity molecular tests with an extraction step.
VERBATIM QUESTION: Are the recommended PPAs for antigen tests applicable to symptomatic individuals?
VERBATIM ANSWER: And those PPAs are in symptomatic individuals. And the comparator test can be, you know, the recently granted molecular test and any subsequent ones coming in for full authorization could use that test. But then if you use the EUA authorized comparators as long as they are high sensitivity molecular tests with an extraction step.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen test PPAs, Symptomatic individuals, Comparator test requirements
REVIEW FLAG: False

QA Block 2-7
CLARIFIED QUESTION: What is the significance of the templates provided on the FDA website for EUA requests?
CLARIFIED ANSWER: The FDA has provided EUA templates for serology, antigen, and molecular tests on its website, which reflect the FDA's current approach to the data and information required to support the EUA review process.
VERBATIM QUESTION: What is the significance of the templates provided on the FDA website for EUA requests?
VERBATIM ANSWER: We do have the EUA templates for serology, antigen and molecular test up on our Web site and ask that you submit your EUA request to cdrh-eua- templates@fda.hhs.gov . Those templates generally reflect our current thinking on the data and information that developers should submit to facilitate the EUA review process.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA templates, Submission process, Review facilitation
REVIEW FLAG: False

QA Block 2-8
CLARIFIED QUESTION: What steps does the FDA take after receiving an EUA request from a developer?
CLARIFIED ANSWER: After receiving an EUA request, the FDA reviews it to determine if it sufficiently supports EUA authorization. If sufficient, the FDA authorizes the test, issues a sponsor letter of authorization, and lists the test on the FDA landing page.
VERBATIM QUESTION: What steps does the FDA take after receiving an EUA request from a developer?
VERBATIM ANSWER: Once we receive that we review your EUA request and determine whether it is sufficient to support an EUA authorization. And then at that point if we do believe it's sufficient, we would authorize the test then issue the sponsor letter of authorization and add that test to the FDA landing page.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA process steps, EUA review, FDA authorization steps
REVIEW FLAG: False

QA Block 2-9
CLARIFIED QUESTION: Is a predicate test needed for EUA submissions, and how does the comparator test differ in this context?
CLARIFIED ANSWER: An EUA review does not require a predicate test, as it is not a substantial equivalence determination. However, a comparator test is often requested. FDA recommends a 90% PPA for OTC antigen tests using the non-lab template or 80% PPA for serial testing claims per the recent supplemental template.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: So just to clarify some terminology there, for an EUA review, it is different than a 510k review. So for an EUA, it is not a substantial equivalence determination so there is no predicate. But we do often, you know, ask for a comparator test to be used in your clinical evaluation so I think that's likely what this question is referring to. And we do recommend for OTC tests in the antigen the - sorry, the non-lab template, we do recommend a minimum of 90% PPA for OTC tests as compared to the comparator test. And in the new supplemental template issued last week we recommend a minimum of 80% PPA for serial testing claims.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA review, Comparator test, OTC antigen test
REVIEW FLAG: False

QA Block 2-10
CLARIFIED QUESTION: What are the FDA's recommendations for minimum PPA for over-the-counter (OTC) antigen tests evaluated using the non-lab template?
CLARIFIED ANSWER: The FDA recommends a minimum of 90% PPA for OTC antigen tests using the non-lab template compared to a comparator test, and 80% PPA for serial testing claims in the supplemental template.
VERBATIM QUESTION: What are the FDA's recommendations for minimum PPA for over-the-counter (OTC) antigen tests evaluated using the non-lab template?
VERBATIM ANSWER: We do recommend for OTC tests in the antigen the - sorry, the non-lab template, we do recommend a minimum of 90% PPA for OTC tests as compared to the comparator test. And in the new supplemental template issued last week we recommend a minimum of 80% PPA for serial testing claims.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: OTC antigen test PPA, Non-lab template, Supplemental template PPA
REVIEW FLAG: False

QA Block 2-11
CLARIFIED QUESTION: Are molecular tests with EUA authorization and high sensitivity an acceptable choice as comparator tests?
CLARIFIED ANSWER: Yes, molecular tests with EUA authorization and high sensitivity, including an extraction step, are acceptable comparator tests.
VERBATIM QUESTION: Are molecular tests with EUA authorization and high sensitivity an acceptable choice as comparator tests?
VERBATIM ANSWER: And the comparator test can be, you know, the recently granted molecular test and any subsequent ones coming in for full authorization could use that test. But then if you use the EUA authorized comparators as long as they are high sensitivity molecular tests with an extraction step.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA comparator tests, Molecular test acceptance, High sensitivity
REVIEW FLAG: False

QA Block 2-12
CLARIFIED QUESTION: What qualifies a molecular test for use as a comparator based on its sensitivity and method of operation (e.g., extraction step)?
CLARIFIED ANSWER: A molecular test can qualify as a comparator if it is either a recently granted molecular test or an EUA-authorized high-sensitivity molecular test with an extraction step.
VERBATIM QUESTION: What qualifies a molecular test for use as a comparator based on its sensitivity and method of operation (e.g., extraction step)?
VERBATIM ANSWER: And the comparator test can be, you know, the recently granted molecular test and any subsequent ones coming in for full authorization could use that test. But then if you use the EUA authorized comparators as long as they are high sensitivity molecular tests with an extraction step.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Comparator test criteria, Molecular test sensitivity, Extraction step requirement
REVIEW FLAG: False


#### 3. BioFire de Novo as Predicate for 510(k) Submissions

QA Block 3-1
CLARIFIED QUESTION: Is the BioFire test the only one that can be used as a predicate for subsequent submissions by other manufacturers?
CLARIFIED ANSWER: The BioFire test is the only legally marketed predicate for a 510(k) submission until other tests are cleared through the 510(k) pathway. For clinical evaluation comparators, BioFire or an EUA-authorized, highly sensitive RT-PCR assay can be used. FDA recommends submitting a pre-submission to discuss validation strategies and comparator methods when pursuing the 510(k) pathway.
VERBATIM QUESTION: Is the BioFire test the only one that can be used as a predicate for subsequent submissions by other manufacturers?
VERBATIM ANSWER: So since BioFire was entered a de novo they are currently the only legally marketed predicate for a 510k submission until subsequent tests are also cleared through the 510k pathway. So for future 510k submissions BioFire is currently the predicate to use there. But for your comparator, for your clinical evaluation you can use BioFire but you also can use an EUA authorized highly sensitive RT-PCR assay for the clinical evaluation as well as for EUA requests. And we do recommend that if you intend to pursue the 510k pathway that you submit a pre-submission to discuss your proposed validation strategies and your comparator methods.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: BioFire test predicate, 510(k) submission, validation strategies
REVIEW FLAG: False

QA Block 3-2
CLARIFIED QUESTION: What is the appropriate comparator for a clinical evaluation when submitting a 510k for a COVID-19 diagnostic test?
CLARIFIED ANSWER: The appropriate comparator for a clinical evaluation when submitting a 510(k) for a COVID-19 diagnostic test can be BioFire or an EUA-authorized highly sensitive RT-PCR assay.
VERBATIM QUESTION: What is the appropriate comparator for a clinical evaluation when submitting a 510k for a COVID-19 diagnostic test?
VERBATIM ANSWER: But for your comparator, for your clinical evaluation you can use BioFire but you also can use an EUA authorized highly sensitive RT-PCR assay for the clinical evaluation as well as for EUA requests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: 510k submissions, clinical evaluation comparator, COVID-19 diagnostic tests
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: Can an EUA-authorized RT-PCR assay be used as a comparator for EUA requests?
CLARIFIED ANSWER: An EUA-authorized highly sensitive RT-PCR assay can be used as a comparator for clinical evaluations and EUA requests.
VERBATIM QUESTION: Can an EUA-authorized RT-PCR assay be used as a comparator for EUA requests?
VERBATIM ANSWER: But for your comparator, for your clinical evaluation you can use BioFire but you also can use an EUA authorized highly sensitive RT-PCR assay for the clinical evaluation as well as for EUA requests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: comparators, EUA requests, RT-PCR assays
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: How should developers intending to pursue the 510k pathway approach validation strategies and comparator methods?
CLARIFIED ANSWER: Developers pursuing the 510k pathway should submit a pre-submission to the FDA to discuss proposed validation strategies and comparator methods.
VERBATIM QUESTION: How should developers intending to pursue the 510k pathway approach validation strategies and comparator methods?
VERBATIM ANSWER: We do recommend that if you intend to pursue the 510k pathway that you submit a pre-submission to discuss your proposed validation strategies and your comparator methods.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: 510k pathway, validation strategies, comparator methods
REVIEW FLAG: False

QA Block 3-5
CLARIFIED QUESTION: Are initial serology or antigen test applications required to go through the de novo pathway?
CLARIFIED ANSWER: FDA confirms that initial serology or antigen test applications would need to go through the de novo pathway, as none have been granted to date.
VERBATIM QUESTION: Are initial serology or antigen test applications required to go through the de novo pathway?
VERBATIM ANSWER: And I would just add, since we have not granted a serology test or an antigen test that those initial applications would be through the de novo pathway.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: de novo pathway, serology and antigen tests, FDA application process
REVIEW FLAG: False


#### 4. FDA Guidelines for Respiratory Panel Authorization Studies

QA Block 4-1
CLARIFIED QUESTION: Does an EUA request under review for a similar expanded respiratory panel RSV and SARS-CoV-2 need to perform clinical studies this year given the low influenza prevalence?
CLARIFIED ANSWER: The FDA remains committed to reviewing EUA requests to address public health needs and cannot predict when the public health emergency will end.
VERBATIM QUESTION: Does an EUA request under review for a similar expanded respiratory panel RSV and SARS-CoV-2 need to perform clinical studies this year given the low influenza prevalence?
VERBATIM ANSWER: We obviously can't anticipate when the public health emergency will end but we are committed to helping to ensure that the public has access to a wide variety of test of options for COVID-19. And we do intend to continue to review EUAs to address the public health needs.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA review process, COVID-19 diagnostic tests
REVIEW FLAG: False

QA Block 4-2
CLARIFIED QUESTION: Would the expanded respiratory panel EUAs be able to remain in place despite low influenza prevalence?
CLARIFIED ANSWER: The BioFire de novo authorization does not impact EUAs for other developers or tests beyond its own identical test, which was revoked when the de novo was granted. FDA remains committed to reviewing EUAs based on public health needs.
VERBATIM QUESTION: Would the expanded respiratory panel EUAs be able to remain in place despite low influenza prevalence?
VERBATIM ANSWER: And so I do want to clarify that the BioFire de novo does not impact any EUAs other than their own for that identical test which we revoked concurrent to granting the de novo for the same test. BioFire's other EUAs including the point of care test as well as EUAs for other - where other developers were not impacted. We obviously can't anticipate when the public health emergency will end but we are committed to helping to ensure that the public has access to a wide variety of test of options for COVID-19. And we do intend to continue to review EUAs to address the public health needs.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA continuation, Respiratory panel, Low influenza prevalence
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: Is FDA open to the use of archived specimens to pursue clearance of an extended respiratory panel including flu A, flu B, RSV A&B, and SARS-CoV-2?
CLARIFIED ANSWER: FDA is open to the use of archived specimens for EUA clearance of a respiratory panel including flu A, flu B, RSV A&B, and SARS-CoV-2. However, a prospective clinical study is generally required. During the public health emergency, archived samples may be tested at one site, but post-authorization, FDA requires further prospective studies at multiple sites.
VERBATIM QUESTION: Is FDA open to the use of archived specimens to pursue clearance of an extended respiratory panel including flu A, flu B, RSV A&B, and SARS-CoV-2?
VERBATIM ANSWER: So generally to evaluate the clinical performance of your multi-analyte test a prospective clinical study should be conducted. Considering the public health needs in the current emergency, a clinical performance study in support of your EUA request may be conducted at one site testing archived, positive and negative clinical samples with known specimen types. The pre-selection of archived positive samples should represent a range of viral load or CT values including low positive samples near the assay's cut off. And since this is typically for a device that has not been -- excuse me -- FDA cleared for the respiratory pathogens included in the test and it's likely that the test will be used in patients with respiratory symptoms in lieu of an FDA cleared respiratory panel, we do intend to include a condition of authorization that you conduct a post EUA the post authorization prospective clinical study that would include a minimum of three sample collection sites and three testing sites prospectively in patients with general respiratory symptoms.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Use of archived specimens, EUA for respiratory panel, Prospective studies
REVIEW FLAG: False

QA Block 4-5
CLARIFIED QUESTION: Will EUAs for non-identical tests to BioFire remain valid despite the transition of BioFire's test to a de novo authorization?
CLARIFIED ANSWER: The FDA confirms that the BioFire de novo authorization does not affect EUAs for non-identical tests. Only the EUA for the identical test was impacted and revoked upon granting of the de novo authorization.
VERBATIM QUESTION: Will EUAs for non-identical tests to BioFire remain valid despite the transition of BioFire's test to a de novo authorization?
VERBATIM ANSWER: The BioFire de novo does not impact any EUAs other than their own for that identical test which we revoked concurrent to granting the de novo for the same test. BioFire's other EUAs including the point of care test as well as EUAs for other - where other developers were not impacted.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: BioFire de novo authorization, Impact on non-identical EUAs, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 4-6
CLARIFIED QUESTION: What options does the FDA provide for developers if viruses like influenza and RSV are at low prevalence during clinical studies?
CLARIFIED ANSWER: The FDA allows developers to use archived specimens for evaluating clinical performance during EUA requests and for pursuing full authorizations when low virus prevalence makes prospective studies infeasible. These studies must represent various viral loads and include conditions for post-market prospective studies.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: Considering the public health needs in the current emergency, a clinical performance study in support of your EUA request may be conducted at one site testing archived, positive and negative clinical samples with known specimen types. The pre-selection of archived positive samples should represent a range of viral load or CT values including low positive samples near the assay's cut off. And since this is typically for a device that has not been FDA cleared for the respiratory pathogens included in the test and it's likely that the test will be used in patients with respiratory symptoms in lieu of an FDA cleared respiratory panel, we do intend to include a condition of authorization that you conduct a post EUA the post authorization prospective clinical study that would include a minimum of three sample collection sites and three testing sites prospectively in patients with general respiratory symptoms. And if someone is interested in pursuing a full authorization of an EUA panel we would still allow some archived sample use, however, we would ask for that prospective clinical study for the conversion to a full authorization and collect as many positives as feasible. You know, we understand that some respiratory viruses especially flu are very low in circulation even during peak respiratory season during the pandemic. And so the recently authorized BioFire and de novo in the special controls does speak to this use of archived samples if the prospective study demonstrates low prevalence of certain viruses.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA clinical studies, Low virus prevalence, Use of archived samples
REVIEW FLAG: False

QA Block 4-7
CLARIFIED QUESTION: What are the expectations for archived sample selection regarding viral load or CT value representation for EUA submissions?
CLARIFIED ANSWER: FDA stated that a clinical performance study for an EUA may involve testing archived positive and negative clinical samples with known specimen types at one site. Archived positive samples must include a range of viral load or CT values, particularly near the assay's cutoff.
VERBATIM QUESTION: What are the expectations for archived sample selection regarding viral load or CT value representation for EUA submissions?
VERBATIM ANSWER: Considering the public health needs in the current emergency, a clinical performance study in support of your EUA request may be conducted at one site testing archived, positive and negative clinical samples with known specimen types. The pre-selection of archived positive samples should represent a range of viral load or CT values including low positive samples near the assay's cut off.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submissions, Archived sample selection, Viral load/CT values
REVIEW FLAG: False

QA Block 4-8
CLARIFIED QUESTION: What conditions of authorization apply to tests likely to be used in patients with general respiratory symptoms in lieu of an FDA-cleared respiratory panel?
CLARIFIED ANSWER: For devices likely used in patients with respiratory symptoms, FDA intends to include a condition of authorization that requires a post-EUA prospective clinical study with at least three sample collection and three testing sites.
VERBATIM QUESTION: What conditions of authorization apply to tests likely to be used in patients with general respiratory symptoms in lieu of an FDA-cleared respiratory panel?
VERBATIM ANSWER: And since this is typically for a device that has not been -- excuse me -- FDA cleared for the respiratory pathogens included in the test and it's likely that the test will be used in patients with respiratory symptoms in lieu of an FDA cleared respiratory panel, we do intend to include a condition of authorization that you conduct a post EUA the post authorization prospective clinical study that would include a minimum of three sample collection sites and three testing sites prospectively in patients with general respiratory symptoms.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Conditions of authorization, Post-EUA study, Respiratory panels
REVIEW FLAG: False

QA Block 4-9
CLARIFIED QUESTION: Does the FDA require a post-authorization prospective clinical study involving multiple sites for initially authorized multi-analyte respiratory panels?
CLARIFIED ANSWER: The FDA requires a post-authorization prospective clinical study for initially authorized multi-analyte respiratory panels involving at least three sample collection sites and three testing sites, conducted prospectively with patients exhibiting general respiratory symptoms.
VERBATIM QUESTION: Does the FDA require a post-authorization prospective clinical study involving multiple sites for initially authorized multi-analyte respiratory panels?
VERBATIM ANSWER: And since this is typically for a device that has not been -- excuse me -- FDA cleared for the respiratory pathogens included in the test and it's likely that the test will be used in patients with respiratory symptoms in lieu of an FDA cleared respiratory panel, we do intend to include a condition of authorization that you conduct a post EUA the post authorization prospective clinical study that would include a minimum of three sample collection sites and three testing sites prospectively in patients with general respiratory symptoms.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: post-authorization study, multi-analyte respiratory panels, clinical study requirements
REVIEW FLAG: False

QA Block 4-10
CLARIFIED QUESTION: For a full EUA to traditional authorization conversion, what specific data requirements need to be submitted if using archived samples?
CLARIFIED ANSWER: For converting an EUA panel to full traditional authorization, the FDA permits the use of some archived samples but requires a prospective clinical study to support the conversion, aiming to collect as many positive cases as feasible, particularly where there is low viral prevalence.
VERBATIM QUESTION: For a full EUA to traditional authorization conversion, what specific data requirements need to be submitted if using archived samples?
VERBATIM ANSWER: And if someone is interested in pursuing a full authorization of an EUA panel we would still allow some archived sample use, however, we would ask for that prospective clinical study for the conversion to a full authorization and collect as many positives as feasible. You know, we understand that some respiratory viruses especially flu are very low in circulation even during peak respiratory season during the pandemic. And so the recently authorized BioFire and de novo in the special controls does speak to this use of archived samples if the prospective study demonstrates low prevalence of certain viruses.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA conversion requirements, Archived samples, Prospective clinical studies
REVIEW FLAG: False

QA Block 4-11
CLARIFIED QUESTION: How should developers handle the inclusion of viruses at low circulation in clinical studies due to pandemic conditions?
CLARIFIED ANSWER: FDA acknowledges low circulation levels of respiratory viruses like flu and allows the use of archived samples when prospective studies show low virus prevalence.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: We understand that some respiratory viruses especially flu are very low in circulation even during peak respiratory season during the pandemic. And so the recently authorized BioFire and de novo in the special controls does speak to this use of archived samples if the prospective study demonstrates low prevalence of certain viruses.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: low virus prevalence, use of archived samples, clinical study requirements
REVIEW FLAG: False


#### 5. EUA Requirements for Prescription and OTC Lateral Flow Tests

QA Block 5-1
CLARIFIED QUESTION: What are the differences in EUA requirements between prescription use lateral flow antigen tests and non-prescription use lateral flow antigen tests?
CLARIFIED ANSWER: The FDA requires clinical evaluation to be conducted in settings corresponding to test indication. Asymptomatic screening claims require population-based validation. OTC tests for lay users also need usability and user comprehension data, while serial screening claims may rely on symptomatic validation per the supplemental template.
VERBATIM QUESTION: What are the differences in EUA requirements between prescription use lateral flow antigen tests and non-prescription use lateral flow antigen tests?
VERBATIM ANSWER: Generally the recommendation for analytical and clinical validation are included in the EUA template. And we expect that the clinical evaluation be conducted in the appropriate setting such as point of care or at home depending on the proposed indication. If you are seeking an asymptomatic screening claim you should validate in that population. Though as we have discussed in the supplemental template issued last week you may request a serial screening claim based only on symptomatic validation. Additionally for tests intended to be performed by lay users you should submit usability data. And for OTC tests for the lay user who will also receive and interpret the results themselves, we would expect user comprehension data.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA requirements, Lateral flow antigen tests, Prescription vs non-prescription
REVIEW FLAG: False

QA Block 5-2
CLARIFIED QUESTION: For tests intended for lay users, what usability data should be submitted?
CLARIFIED ANSWER: For tests intended for lay users, the FDA requires submission of usability data. If the test is OTC and lay users interpret the results themselves, user comprehension data is also expected.
VERBATIM QUESTION: For tests intended for lay users, what usability data should be submitted?
VERBATIM ANSWER: Additionally for tests intended to be performed by lay users you should submit usability data. And for OTC tests for the lay user who will also receive and interpret the results themselves, we would expect user comprehension data.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Usability data for lay users, OTC test requirements
REVIEW FLAG: False

QA Block 5-3
CLARIFIED QUESTION: For OTC tests where lay users receive and interpret results, what user comprehension data is expected?
CLARIFIED ANSWER: The FDA expects user comprehension data for OTC tests where lay users receive and interpret the results themselves.
VERBATIM QUESTION: For OTC tests where lay users receive and interpret results, what user comprehension data is expected?
VERBATIM ANSWER: And for OTC tests for the lay user who will also receive and interpret the results themselves, we would expect user comprehension data.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: OTC test requirements, User comprehension data
REVIEW FLAG: False

QA Block 5-4
CLARIFIED QUESTION: Can data from asymptomatic individuals for an OTC claim be collected post-authorization?
CLARIFIED ANSWER: For non-prescription OTC tests, FDA generally expects asymptomatic validation pre-authorization. However, asymptomatic data can be collected post-authorization for a serial screening claim when symptomatic performance is at least 80% as per the supplemental template.
VERBATIM QUESTION: Can data from asymptomatic individuals for an OTC claim be collected post-authorization?
VERBATIM ANSWER: So generally for non-prescription tests we do expect that they will include a claim for asymptomatic screening since there would not be a healthcare provider involved to determine if the individual has symptoms or is otherwise suspected of COVID-19. And generally we do expect to see that symptomatic - sorry, the asymptomatic validation pre-authorization. But in the case of serial screening per the supplemental template we will consider authorizing that claim with a post-authorization condition to establish performance with asymptomatic individuals when your PPA is at least 80% in symptomatic individuals.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Asymptomatic validation, OTC tests, Post-authorization data
REVIEW FLAG: False

QA Block 5-5
CLARIFIED QUESTION: What are the conditions under which a serial screening claim can be authorized with post-authorization data collection for asymptomatic individuals?
CLARIFIED ANSWER: The FDA may authorize a serial screening claim with post-authorization data collection for asymptomatic individuals if the test demonstrates a Positive Percent Agreement (PPA) of at least 80% in symptomatic individuals, per the supplemental template.
VERBATIM QUESTION: What are the conditions under which a serial screening claim can be authorized with post-authorization data collection for asymptomatic individuals?
VERBATIM ANSWER: But in the case of serial screening per the supplemental template we will consider authorizing that claim with a post- authorization condition to establish performance with asymptomatic individuals when your PPA is at least 80% in symptomatic individuals.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: serial screening claim, post-authorization data, asymptomatic validation
REVIEW FLAG: False

QA Block 5-6
CLARIFIED QUESTION: What throughput or capacity qualifies a test as high or low volume in the context of EUA reviews?
CLARIFIED ANSWER: The FDA does not provide specific metrics for high or low throughput qualification but prioritizes tests that increase testing capacity, reduce dependence on supplies, and serve public health needs. For clarification on a specific test, contact the EUA mailbox.
VERBATIM QUESTION: What throughput or capacity qualifies a test as high or low volume in the context of EUA reviews?
VERBATIM ANSWER: We received a question about high volume and low volume settings or tests for a lateral flow test. And we have discussed this previously where we do prioritize review of EUA requests where authorization would significantly increase testing capacity such as tests that reduce reliance on test supplies and try to report widely distributed tests to address public health needs. We can't unfortunately provide specific numbers of what we consider to be high or low volume or throughput. But if you need help determining whether your test would be considered high testing capacity we recommend that you reach out through the EUA mailbox with information about the features of your test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA test throughput, high and low volume definitions, testing priority guidance
REVIEW FLAG: False

QA Block 5-7
CLARIFIED QUESTION: How can developers determine if their test would be considered high testing capacity for EUA review?
CLARIFIED ANSWER: FDA recommends contacting the EUA mailbox with details about the features of the test for assistance in determining if it qualifies as high testing capacity, as specific volume thresholds are not provided.
VERBATIM QUESTION: How can developers determine if their test would be considered high testing capacity for EUA review?
VERBATIM ANSWER: We can't unfortunately provide specific numbers of what we consider to be high or low volume or throughput. But if you need help determining whether your test would be considered high testing capacity we recommend that you reach out through the EUA mailbox with information about the features of your test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA review process, testing capacity determination
REVIEW FLAG: False

QA Block 5-8
CLARIFIED QUESTION: What are the recommended analytical and clinical validation procedures for point-of-care settings?
CLARIFIED ANSWER: The FDA recommends following the EUA template for analytical and clinical validation procedures. Clinical evaluations should occur in appropriate settings, including point-of-care, based on the test's proposed use.
VERBATIM QUESTION: What are the recommended analytical and clinical validation procedures for point-of-care settings?
VERBATIM ANSWER: Generally the recommendation for analytical and clinical validation are included in the EUA template. And we expect that the clinical evaluation be conducted in the appropriate setting such as point of care or at home depending on the proposed indication.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: analytical and clinical validation, point-of-care settings, EUA template
REVIEW FLAG: False

QA Block 5-9
CLARIFIED QUESTION: What criteria determine the appropriate settings for clinical evaluations?
CLARIFIED ANSWER: Clinical evaluations should be conducted in appropriate settings like point of care or at home based on the test's indication. Asymptomatic screening claims require validation in the intended population, though serial screening claims may use symptomatic validation as per the supplemental template.
VERBATIM QUESTION: What criteria determine the appropriate settings for clinical evaluations?
VERBATIM ANSWER: We expect that the clinical evaluation be conducted in the appropriate setting such as point of care or at home depending on the proposed indication. If you are seeking an asymptomatic screening claim you should validate in that population. Though as we have discussed in the supplemental template issued last week you may request a serial screening claim based only on symptomatic validation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: clinical evaluation settings, asymptomatic screening, serial screening validation
REVIEW FLAG: False

QA Block 5-10
CLARIFIED QUESTION: How can a developer validate a test for asymptomatic screening claims?
CLARIFIED ANSWER: To validate a test for asymptomatic screening, the FDA recommends validation in the asymptomatic population. Alternatively, developers may request a serial screening claim based on symptomatic validation, as outlined in the supplemental EUA template.
VERBATIM QUESTION: How can a developer validate a test for asymptomatic screening claims?
VERBATIM ANSWER: If you are seeking an asymptomatic screening claim you should validate in that population. Though as we have discussed in the supplemental template issued last week you may request a serial screening claim based only on symptomatic validation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: asymptomatic screening validation, EUA requirements, serial screening claims
REVIEW FLAG: False

QA Block 5-11
CLARIFIED QUESTION: What are the FDA's expectations for serial screening validation based on symptomatic use?
CLARIFIED ANSWER: The FDA allows serial screening claims based on symptomatic validation as outlined in the supplemental template. For lay-user tests, usability data must be submitted.
VERBATIM QUESTION: What are the FDA's expectations for serial screening validation based on symptomatic use?
VERBATIM ANSWER: Though as we have discussed in the supplemental template issued last week you may request a serial screening claim based only on symptomatic validation. Additionally for tests intended to be performed by lay users you should submit usability data.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: serial screening, symptomatic validation, usability data
REVIEW FLAG: False

QA Block 5-12
CLARIFIED QUESTION: Does the FDA consider usability and user comprehension data mandatory for OTC tests?
CLARIFIED ANSWER: The FDA requires usability data for lay-user performed tests and user comprehension data for OTC tests where lay users interpret results themselves.
VERBATIM QUESTION: Does the FDA consider usability and user comprehension data mandatory for OTC tests?
VERBATIM ANSWER: Additionally for tests intended to be performed by lay users you should submit usability data. And for OTC tests for the lay user who will also receive and interpret the results themselves, we would expect user comprehension data.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: OTC test usability requirements, User comprehension data
REVIEW FLAG: False

QA Block 5-15
CLARIFIED QUESTION: How should developers submit information about their test features for consideration as a high-capacity testing option?
CLARIFIED ANSWER: FDA recommends reaching out through the EUA mailbox with details about your test features if you need assistance determining whether your test qualifies as high testing capacity.
VERBATIM QUESTION: How should developers submit information about their test features for consideration as a high-capacity testing option?
VERBATIM ANSWER: If you need help determining whether your test would be considered high testing capacity we recommend that you reach out through the EUA mailbox with information about the features of your test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: test capacity, EUA submissions, high-capacity tests
REVIEW FLAG: False

QA Block 5-16
CLARIFIED QUESTION: Why are lateral flow tests prioritized in point-of-care or home settings instead of high-throughput laboratory use?
CLARIFIED ANSWER: Lateral flow tests are single-use devices, making them unsuitable for high-throughput labs. Their value lies in point-of-care or home environments, leading them to be prioritized for these settings.
VERBATIM QUESTION: Why are lateral flow tests prioritized in point-of-care or home settings instead of high-throughput laboratory use?
VERBATIM ANSWER: Lateral flow devices are one at a time devices and if they are being performed in a high or moderately complex lab they are not high throughput tests. And so their prime value in the pandemic is in the point of care or potentially the home setting. So that's where we focus our priority reviews for lateral flow devices.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Lateral flow test prioritization, Point-of-care, Home diagnostics
REVIEW FLAG: False


#### 6. Reporting Requirements for Over-the-Counter Home Test Kits

QA Block 6-1
CLARIFIED QUESTION: Are over-the-counter COVID-19 test kits required to report results to public health authorities?
CLARIFIED ANSWER: The FDA encourages developers of at-home COVID-19 tests to include result reporting mechanisms but does not require it for authorization. In some cases, conditions of authorization may include developing such mechanisms post-approval.
VERBATIM QUESTION: Are over-the-counter COVID-19 test kits required to report results to public health authorities?
VERBATIM ANSWER: We do encourage developers of home tests to include mechanisms for reporting results to public health authorities. We don't intend to hold up authorizations of home tests that do not have this. But we have in some cases included the development of such a mechanism as a condition of authorization for a home test that we have authorized before that test has been available.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: COVID-19 over-the-counter tests, Result reporting requirements, FDA test authorization conditions
REVIEW FLAG: False

QA Block 6-2
CLARIFIED QUESTION: Does the FDA have specific recommendations on mechanisms for reporting home test results to public health authorities?
CLARIFIED ANSWER: The FDA encourages developers to include mechanisms for reporting home test results to public health authorities. While authorizations aren't delayed for lack of such mechanisms, they might be added as a condition of authorization. Reporting data is seen as useful for managing the pandemic, and advancements are being made by HHS to streamline pathways for such reporting.
VERBATIM QUESTION: Does the FDA have specific recommendations on mechanisms for reporting home test results to public health authorities?
VERBATIM ANSWER: We do encourage developers of home tests to include mechanisms for reporting results to public health authorities. We don't intend to hold up authorizations of home tests that do not have this. But we have in some cases included the development of such a mechanism as a condition of authorization for a home test that we have authorized before that test has been available. And absolutely we see the reporting of data from all types of tests as useful for managing this pandemic. And any method that can, I don't know, streamline the reporting of that would be helpful. And HHS administration have been working on pathways to do this and they continue to make advances. And we would refer you to them and their announcements on the availability of reporting features.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: home test reporting, public health authorities, FDA guidance
REVIEW FLAG: False

QA Block 6-3
CLARIFIED QUESTION: Under what circumstances is the development of a reporting mechanism included as a condition of authorization for a home COVID-19 test?
CLARIFIED ANSWER: The FDA has sometimes made the development of a reporting mechanism a condition of authorization for a home test, particularly when the test has been authorized before being made available.
VERBATIM QUESTION: Under what circumstances is the development of a reporting mechanism included as a condition of authorization for a home COVID-19 test?
VERBATIM ANSWER: We don't intend to hold up authorizations of home tests that do not have this. But we have in some cases included the development of such a mechanism as a condition of authorization for a home test that we have authorized before that test has been available.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: home COVID-19 tests, authorization conditions, reporting mechanisms
REVIEW FLAG: False

QA Block 6-4
CLARIFIED QUESTION: How much time after authorization is typically allowed for developers to implement reporting mechanisms for home tests?
CLARIFIED ANSWER: Some period of time after authorization is allowed for implementing reporting mechanisms for home tests. The FDA and HHS are working on improving reporting pathways.
VERBATIM QUESTION: How much time after authorization is typically allowed for developers to implement reporting mechanisms for home tests?
VERBATIM ANSWER: And that's some period of time after authorization. And absolutely we see the reporting of data from all types of tests as useful for managing this pandemic. And any method that can, I don't know, streamline the reporting of that would be helpful. And HHS administration have been working on pathways to do this and they continue to make advances. And we would refer you to them and their announcements on the availability of reporting features.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: reporting timelines, home test authorizations, public health reporting
REVIEW FLAG: False

QA Block 6-5
CLARIFIED QUESTION: What methods does the FDA consider effective for streamlining the reporting of data from COVID-19 tests?
CLARIFIED ANSWER: FDA values the reporting of data from all types of tests as essential for managing the pandemic, and supports any methods that streamline this process. HHS is actively working on pathways and announcements for reporting features.
VERBATIM QUESTION: What methods does the FDA consider effective for streamlining the reporting of data from COVID-19 tests?
VERBATIM ANSWER: And absolutely we see the reporting of data from all types of tests as useful for managing this pandemic. And any method that can, I don't know, streamline the reporting of that would be helpful. And HHS administration have been working on pathways to do this and they continue to make advances. And we would refer you to them and their announcements on the availability of reporting features. Thank you.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Data reporting, COVID-19 tests, HHS reporting pathways
REVIEW FLAG: False

QA Block 6-6
CLARIFIED QUESTION: What types of advances in reporting mechanisms have been made by the HHS administration?
CLARIFIED ANSWER: The HHS administration is actively working on pathways for reporting data and continues to make advancements. Updates can be found in their announcements regarding reporting features.
VERBATIM QUESTION: What types of advances in reporting mechanisms have been made by the HHS administration?
VERBATIM ANSWER: And HHS administration have been working on pathways to do this and they continue to make advances. And we would refer you to them and their announcements on the availability of reporting features.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: reporting mechanisms, HHS administration, COVID-19 testing
REVIEW FLAG: False

QA Block 6-7
CLARIFIED QUESTION: Where can developers find announcements or updates from HHS on the availability of reporting features for COVID-19 tests?
CLARIFIED ANSWER: Developers can find updates on the availability of COVID-19 test reporting features from HHS announcements.
VERBATIM QUESTION: Where can developers find announcements or updates from HHS on the availability of reporting features for COVID-19 tests?
VERBATIM ANSWER: And HHS administration have been working on pathways to do this and they continue to make advances. And we would refer you to them and their announcements on the availability of reporting features.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: HHS reporting updates, COVID-19 test reporting, developer resources
REVIEW FLAG: False


#### 7. Assay Controls and Validity in At-Home Tests

QA Block 7-1
CLARIFIED QUESTION: Why does the FDA believe external controls are important for quality control and training in COVID-19 home tests?
CLARIFIED ANSWER: The FDA believes external controls are important for quality control and training, but generally not necessary for at-home COVID-19 tests.
VERBATIM QUESTION: Why does the FDA believe external controls are important for quality control and training in COVID-19 home tests?
VERBATIM ANSWER: We do generally believe that external controls are important for quality control and training, but we don't think that they are typically needed for at home tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: external controls, COVID-19 home tests, quality control
REVIEW FLAG: False

QA Block 7-2
CLARIFIED QUESTION: What is the FDA's rationale for not typically requiring external controls for at-home tests?
CLARIFIED ANSWER: The FDA considers external controls important for quality control and training but does not typically require them for at-home tests. FDA recommends internal controls to ensure valid test results.
VERBATIM QUESTION: What is the FDA's rationale for not typically requiring external controls for at-home tests?
VERBATIM ANSWER: And so we do generally believe that external controls are important for quality control and training, but we don't think that they are typically needed for at home tests. However, we do recommend that at home tests have an internal control to ensure that the test results are valid.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: at-home test controls, external controls, internal controls
REVIEW FLAG: False

QA Block 7-3
CLARIFIED QUESTION: What specific characteristics should internal controls in at-home tests have to ensure valid results?
CLARIFIED ANSWER: FDA recommends that at-home tests include internal controls to ensure valid results.
VERBATIM QUESTION: What specific characteristics should internal controls in at-home tests have to ensure valid results?
VERBATIM ANSWER: However, we do recommend that at home tests have an internal control to ensure that the test results are valid.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: assay controls, at-home tests, internal controls
REVIEW FLAG: False

QA Block 7-4
CLARIFIED QUESTION: Are there scenarios where external controls might still be recommended or required for at-home tests?
CLARIFIED ANSWER: FDA believes external controls are typically not needed for at-home tests, though they are important for quality control and training. Internal controls are recommended to ensure valid test results.
VERBATIM QUESTION: Are there scenarios where external controls might still be recommended or required for at-home tests?
VERBATIM ANSWER: And so we do generally believe that external controls are important for quality control and training, but we don't think that they are typically needed for at home tests. However, we do recommend that at home tests have an internal control to ensure that the test results are valid.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: external controls, internal controls, at-home tests
REVIEW FLAG: False

QA Block 7-5
CLARIFIED QUESTION: What is the process for a developer to include an internal control in their at-home test submission?
CLARIFIED ANSWER: The FDA recommends including an internal control in at-home tests to ensure the validity of the test results, though external controls are typically unnecessary.
VERBATIM QUESTION: What is the process for a developer to include an internal control in their at-home test submission?
VERBATIM ANSWER: We do generally believe that external controls are important for quality control and training, but we don't think that they are typically needed for at home tests. However, we do recommend that at home tests have an internal control to ensure that the test results are valid.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Internal controls, Home test development
REVIEW FLAG: False


#### 8. Defining High Throughput Criteria for EUA Approval

QA Block 8-1
CLARIFIED QUESTION: What is the consideration for qualifying as high throughput when using 96 well plates read simultaneously compared to automated 384 well plates?
CLARIFIED ANSWER: FDA advised addressing specific questions regarding the high-throughput qualification of a test offline via email, as the case is assay-specific and requires detailed review.
VERBATIM QUESTION: What is the consideration for qualifying as high throughput when using 96 well plates read simultaneously compared to automated 384 well plates?
VERBATIM ANSWER: Yes. So you have a very assay specific question here and its best handled offline and not on this call so that we can understand the details of your test and see if it doesn't meet our threshold and give guidance for modifications you might be able to make. So your questions are very focused on your specific test and that's best handled offline as the leader of the call has suggested at the beginning of the call. So please go to the next - please make sure that Toby and I are included in your email correspondence on this, and we will make sure that you get a response.
SPEAKER QUESTION: Parvan
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: High-throughput qualification, 96 well vs 384 well plates, EUA review
REVIEW FLAG: False

QA Block 8-2
CLARIFIED QUESTION: If the throughput of the manual process meets or exceeds the throughput of the automated system, should automation be included in the EUA or should a separate EUA be submitted?
CLARIFIED ANSWER: FDA recommends contacting them via email or the pre-EUA process to address the specific case and test details, as the question is very case-specific.
VERBATIM QUESTION: If the throughput of the manual process meets or exceeds the throughput of the automated system, should automation be included in the EUA or should a separate EUA be submitted?
VERBATIM ANSWER: So this is a very specific question for your specific technology and we have invited all developers to send an email to the templates email address or through a pre-EUA process to address whether or not their tests or a specific test will meet our current threshold for priority review. And if you have been unable to get your question answered, please send another email to the template's email address and ask that Toby and Tim be copied and we will respond as quickly as possible to you about your specific situation.
SPEAKER QUESTION: Parvan
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission, Automation and manual throughput
REVIEW FLAG: False

QA Block 8-3
CLARIFIED QUESTION: If 96 well plates are used, but the throughput meets or exceeds the level of automation with 384 well plates, how would it be considered for qualification?
CLARIFIED ANSWER: FDA recommends handling such assay-specific questions offline to discuss details and determine if thresholds are met, with guidance on potential modifications provided as needed.
VERBATIM QUESTION: If 96 well plates are used, but the throughput meets or exceeds the level of automation with 384 well plates, how would it be considered for qualification?
VERBATIM ANSWER: Yes. So you have a very assay specific question here and its best handled offline and not on this call so that we can understand the details of your test and see if it doesn't meet our threshold and give guidance for modifications you might be able to make. So your questions are very focused on your specific test and that's best handled offline as the leader of the call has suggested at the beginning of the call. So please go to the next - please make sure that Toby and I are included in your email correspondence on this, and we will make sure that you get a response. All right. Thank you.
SPEAKER QUESTION: Parvan
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: 96 vs. 384 well plates, high-throughput qualification, FDA EUA guidance
REVIEW FLAG: False

QA Block 8-4
CLARIFIED QUESTION: What are the criteria for determining if a system qualifies as high throughput for EUA priority review?
CLARIFIED ANSWER: FDA advises developers to email their specific assay details to the templates address or initiate a pre-EUA process to understand thresholds for high throughput EUA priority review.
VERBATIM QUESTION: What are the criteria for determining if a system qualifies as high throughput for EUA priority review?
VERBATIM ANSWER: So this is a very specific question for your specific technology and we have invited all developers to send an email to the templates email address or through a pre-EUA process to address whether or not their tests or a specific test will meet our current threshold for priority review. And if you have been unable to get your question answered, please send another email to the template's email address and ask that Toby and Tim be copied and we will respond as quickly as possible to you about your specific situation.
SPEAKER QUESTION: Parvan
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: high throughput criteria, EUA priority review, submission process
REVIEW FLAG: False

QA Block 8-5
CLARIFIED QUESTION: Is there a guidance document that specifies 384 well plates are necessary for high throughput classification?
CLARIFIED ANSWER: FDA recommends contacting the templates email or the pre-EUA process to clarify if a test, such as one with 96 well plates, satisfies their threshold for high throughput classification. Further guidance on modifications will be provided offline.
VERBATIM QUESTION: Is there a guidance document that specifies 384 well plates are necessary for high throughput classification?
VERBATIM ANSWER: So this is a very specific question for your specific technology and we have invited all developers to send an email to the templates email address or through a pre-EUA process to address whether or not their tests or a specific test will meet our current threshold for priority review. And if you have been unable to get your question answered, please send another email to the template's email address and ask that Toby and Tim be copied and we will respond as quickly as possible to you about your specific situation.
SPEAKER QUESTION: Parvan
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: high throughput classification, 96 vs 384 well plates, FDA EUA guidance
REVIEW FLAG: False

QA Block 8-6
CLARIFIED QUESTION: Does the FDA consider manual handling equivalence to automation when determining high throughput status?
CLARIFIED ANSWER: FDA suggests emailing the templates email address or using the pre-EUA process to clarify whether specific tests meet high throughput status requirements.
VERBATIM QUESTION: Does the FDA consider manual handling equivalence to automation when determining high throughput status?
VERBATIM ANSWER: So this is a very specific question for your specific technology and we have invited all developers to send an email to the templates email address or through a pre-EUA process to address whether or not their tests or a specific test will meet our current threshold for priority review. And if you have been unable to get your question answered, please send another email to the template's email address and ask that Toby and Tim be copied and we will respond as quickly as possible to you about your specific situation.
SPEAKER QUESTION: Parvan
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: High throughput requirements, Manual handling vs automation
REVIEW FLAG: False

QA Block 8-7
CLARIFIED QUESTION: What steps should developers take if their test is no longer under active EUA review due to not meeting high throughput classification?
CLARIFIED ANSWER: FDA advises developers to email the templates email address or use the pre-EUA process for questions about meeting thresholds for priority review. Include Toby and Tim in the email for expedited responses.
VERBATIM QUESTION: What steps should developers take if their test is no longer under active EUA review due to not meeting high throughput classification?
VERBATIM ANSWER: So this is a very specific question for your specific technology and we have invited all developers to send an email to the templates email address or through a pre-EUA process to address whether or not their tests or a specific test will meet our current threshold for priority review. And if you have been unable to get your question answered, please send another email to the template's email address and ask that Toby and Tim be copied and we will respond as quickly as possible to you about your specific situation.
SPEAKER QUESTION: Parvan
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA process, High throughput classification, Developer guidance
REVIEW FLAG: False

QA Block 8-8
CLARIFIED QUESTION: Can the FDA provide test-specific guidance for modifications to meet high throughput criteria?
CLARIFIED ANSWER: FDA recommends addressing assay-specific questions offline via email, including relevant FDA contacts for guidance on modifications to meet high throughput criteria.
VERBATIM QUESTION: Can the FDA provide test-specific guidance for modifications to meet high throughput criteria?
VERBATIM ANSWER: Yes. So you have a very assay specific question here and its best handled offline and not on this call so that we can understand the details of your test and see if it doesn't meet our threshold and give guidance for modifications you might be able to make. So your questions are very focused on your specific test and that's best handled offline as the leader of the call has suggested at the beginning of the call. So please go to the next - please make sure that Toby and I are included in your email correspondence on this, and we will make sure that you get a response.
SPEAKER QUESTION: Parvan
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: high throughput criteria, test-specific guidance, email communication
REVIEW FLAG: False


#### 9. Using RT-PCR as Standard for Comparisons

QA Block 9-1
CLARIFIED QUESTION: Is it possible to use an EUA authorized serology test as a comparator rather than an RT-PCR test for the clinical agreement study?
CLARIFIED ANSWER: The FDA continues to recommend RT-PCR tests with high sensitivity as the best comparator for clinical agreement studies due to their reliability. However, applicants can submit alternative validation methods through the pre-EUA process for review.
VERBATIM QUESTION: Is it possible to use an EUA authorized serology test as a comparator rather than an RT-PCR test for the clinical agreement study?
VERBATIM ANSWER: Yes. Thanks for that question. We continue to believe that RT-PCR high sensitivity molecular test with an extraction step remains the best comparator for all comparisons whether they be serology, antigen or molecular. And the serology test can have lower sensitivity and, you know, in the authorized. So for now we are continuing with our recommendation that molecular be the pathway. But as always these are recommendations and if you want to pursue something that's not recommended and get a preview on our thoughts about that validation. You can send the pre-EUA to the template's email address. Thank you.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology test comparators, RT-PCR testing, EUA submissions
REVIEW FLAG: False

QA Block 9-2
CLARIFIED QUESTION: Is there any rationale in requiring only RT-PCR tests as a comparator in the serology template?
CLARIFIED ANSWER: FDA recommends RT-PCR high sensitivity molecular tests with an extraction step as the best comparator for all test types, including serology, due to their higher sensitivity. While this is a recommendation, developers can seek feedback by submitting a pre-EUA.
VERBATIM QUESTION: Is there any rationale in requiring only RT-PCR tests as a comparator in the serology template?
VERBATIM ANSWER: Yes. Thanks for that question. We continue to believe that RT-PCR high sensitivity molecular test with an extraction step remains the best comparator for all comparisons whether they be serology, antigen or molecular. And the serology test can have lower sensitivity and, you know, in the authorized. So for now we are continuing with our recommendation that molecular be the pathway. But as always these are recommendations and if you want to pursue something that's not recommended and get a preview on our thoughts about that validation. You can send the pre-EUA to the template's email address. Thank you.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: RT-PCR as comparator, serology template, test validation
REVIEW FLAG: False

QA Block 9-3
CLARIFIED QUESTION: Why does the FDA recommend RT-PCR tests with an extraction step as the best comparator in clinical agreement studies?
CLARIFIED ANSWER: FDA recommends RT-PCR with an extraction step as the best comparator due to its high sensitivity compared to alternatives such as serology tests, which may have lower sensitivity.
VERBATIM QUESTION: Why does the FDA recommend RT-PCR tests with an extraction step as the best comparator in clinical agreement studies?
VERBATIM ANSWER: We continue to believe that RT-PCR high sensitivity molecular test with an extraction step remains the best comparator for all comparisons whether they be serology, antigen or molecular. And the serology test can have lower sensitivity and, you know, in the authorized. So for now we are continuing with our recommendation that molecular be the pathway. But as always these are recommendations and if you want to pursue something that's not recommended and get a preview on our thoughts about that validation. You can send the pre-EUA to the template's email address. Thank you.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: RT-PCR test, clinical study comparators, sensitivity of serology tests
REVIEW FLAG: False

QA Block 9-4
CLARIFIED QUESTION: Can alternative comparator strategies, such as EUA-authorized serology tests, be submitted for FDA feedback through a pre-EUA?
CLARIFIED ANSWER: The FDA recommends using RT-PCR as the comparator due to its high sensitivity, but alternative strategies like EUA-authorized serology tests may be submitted for feedback through a pre-EUA.
VERBATIM QUESTION: Can alternative comparator strategies, such as EUA-authorized serology tests, be submitted for FDA feedback through a pre-EUA?
VERBATIM ANSWER: Yes. Thanks for that question. We continue to believe that RT-PCR high sensitivity molecular test with an extraction step remains the best comparator for all comparisons whether they be serology, antigen or molecular. And the serology test can have lower sensitivity and, you know, in the authorized. So for now we are continuing with our recommendation that molecular be the pathway. But as always these are recommendations and if you want to pursue something that's not recommended and get a preview on our thoughts about that validation. You can send the pre-EUA to the template's email address.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: alternative comparator strategies, pre-EUA submission, serology tests
REVIEW FLAG: False

QA Block 9-5
CLARIFIED QUESTION: What is the process for submitting a pre-EUA for a non-recommended validation pathway?
CLARIFIED ANSWER: FDA recommends submitting a pre-EUA to the template's email address to seek feedback on non-recommended validation pathways.
VERBATIM QUESTION: What is the process for submitting a pre-EUA for a non-recommended validation pathway?
VERBATIM ANSWER: But as always these are recommendations and if you want to pursue something that's not recommended and get a preview on our thoughts about that validation. You can send the pre-EUA to the template's email address. Thank you.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA submission, validation pathway, FDA recommendations
REVIEW FLAG: False


#### 10. Evaluating Serology Tests for Vaccine Response Effectiveness

QA Block 10-1
CLARIFIED QUESTION: Would a serology assay that looks at the spike protein potentially be a candidate for vaccine response?
CLARIFIED ANSWER: Serology assays targeting the spike protein might be candidates for vaccine response, but their applicability depends on the vaccine. Clinical studies are required to validate such claims, and the FDA is open to submissions that clarify test capabilities.
VERBATIM QUESTION: Would a serology assay that looks at the spike protein potentially be a candidate for vaccine response?
VERBATIM ANSWER: So I think this may be vaccine specific and if a test wants to make a claim that they can detect a specific response then a clinical study, you know, should demonstrate that. So, you know, we don't object clinicians ordering tests off- label. They do that fairly frequently. They prescribe drugs off-label. When they do that they are taking more responsibility obviously for the use of that test or possibly drug. And we just wanted to make sure that they were aware that not every serology test that we have authorized can detect an immune response to every one of the vaccines we haven't analyzed that. But clearly if there is a mis-match then you would theoretically know that an end protein management test would not be positive if the patient has only received a spike protein vaccine. And again we are open to submissions that at least want to clarify this and as this goes forward and clinicians use serology tests in this manner even though they are not authorized for this, we want to make sure that its clear, you know, that, you know, certain tests could potentially be used. So I'm not sure how we are going to do that but we are open to response to what test developers want to do in that regard and so it's probably best to come in with a pre-EUA with something you would like to do and suggest along with some sort of study design.
SPEAKER QUESTION: Elaine Allan
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology assays, spike protein, vaccine response
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: Was it just that particular issue or situation regarding serology tests that were not candidates, and not a blanket statement about all serology tests?
CLARIFIED ANSWER: The FDA clarified that the issue is a theoretical mismatch, not a blanket statement that serology tests are unsuitable. Compatibility depends on the antigen in the vaccine and the serology test, and data is needed to support claims of effectiveness.
VERBATIM QUESTION: Was it just that particular issue or situation regarding serology tests that were not candidates, and not a blanket statement about all serology tests?
VERBATIM ANSWER: Yes, it's a theoretical mis-match. But again you can have a spike protein vaccine - not again but I would say that you could have a, you know, a spike protein vaccine that may not overlap entirely or completely or even at all perhaps with a spike protein. An antigen test depending on what's the antigen in the vaccine and what's the antigen in the serology test. So just because itmake a blank statement that a spike protein serology test, you know, works for a given spike protein vaccine. We would like certainly to make that claim and we would like to look at data that supports that.
SPEAKER QUESTION: Elaine Allan
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology test suitability, vaccine compatibility, data requirements
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: What are the FDA's expectations for clinical studies to demonstrate claims about detecting specific immune responses to vaccines?
CLARIFIED ANSWER: The FDA expects clinical studies, supported by test developers, to demonstrate claims that their tests detect specific immune responses to vaccines. Submissions with study designs related to these claims are encouraged.
VERBATIM QUESTION: What are the FDA's expectations for clinical studies to demonstrate claims about detecting specific immune responses to vaccines?
VERBATIM ANSWER: So I think this may be vaccine specific and if a test wants to make a claim that they can detect a specific response then a clinical study, you know, should demonstrate that. So, you know, we don't object clinicians ordering tests off- label. They do that fairly frequently. They prescribe drugs off-label. When they do that they are taking more responsibility obviously for the use of that test or possibly drug. And we just wanted to make sure that they were aware that not every serology test that we have authorized can detect an immune response to every one of the vaccines we haven't analyzed that. But clearly if there is a mis-match then you would theoretically know that an end protein management test would not be positive if the patient has only received a spike protein vaccine. And again we are open to submissions that at least want to clarify this and as this goes forward and clinicians use serology tests in this manner even though they are not authorized for this, we want to make sure that its clear, you know, that, you know, certain tests could potentially be used. So I'm not sure how we are going to do that but we are open to response to what test developers want to do in that regard and so it's probably best to come in with a pre-EUA with something you would like to do and suggest along with some sort of study design.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: clinical studies, immune response detection, test claims
REVIEW FLAG: False

QA Block 10-4
CLARIFIED QUESTION: How does the FDA recommend addressing theoretical mis-matches between vaccine antigens and authorized serology tests?
CLARIFIED ANSWER: The FDA recommends addressing mismatches by encouraging test developers to submit proposals, such as through a pre-EUA process, with study designs demonstrating test compatibility with specific vaccine antigens.
VERBATIM QUESTION: How does the FDA recommend addressing theoretical mis-matches between vaccine antigens and authorized serology tests?
VERBATIM ANSWER: But clearly if there is a mis-match then you would theoretically know that an end protein management test would not be positive if the patient has only received a spike protein vaccine. And again we are open to submissions that at least want to clarify this and as this goes forward and clinicians use serology tests in this manner even though they are not authorized for this, we want to make sure that its clear, you know, that, you know, certain tests could potentially be used. So I'm not sure how we are going to do that but we are open to response to what test developers want to do in that regard and so it's probably best to come in with a pre-EUA with something you would like to do and suggest along with some sort of study design.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Theoretical mismatches, Serology tests, vaccine antigens
REVIEW FLAG: False

QA Block 10-5
CLARIFIED QUESTION: What is the appropriate process for submitting a pre-EUA related to vaccine-specific serology tests?
CLARIFIED ANSWER: The FDA recommends submitting a pre-EUA with a proposal and study design for vaccine-specific serology tests.
VERBATIM QUESTION: What is the appropriate process for submitting a pre-EUA related to vaccine-specific serology tests?
VERBATIM ANSWER: it's probably best to come in with a pre-EUA with something you would like to do and suggest along with some sort of study design.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Pre-EUA submission, Vaccine-specific serology tests
REVIEW FLAG: False

QA Block 10-6
CLARIFIED QUESTION: What additional details can test developers expect in future FDA communications on serology tests and vaccines?
CLARIFIED ANSWER: The FDA is working on communications regarding serology tests and vaccines, which are in progress. Test developers can seek details either by submitting questions or waiting for official communication once it is finalized.
VERBATIM QUESTION: What additional details can test developers expect in future FDA communications on serology tests and vaccines?
VERBATIM ANSWER: And we are busy, busy with a number of things that are in the works to further expand testing and we always have more than enough to do and Toby has on her list the communication around serology tests and vaccines. So for more details about that you can come in and ask questions or you can wait on her potential communication in the future once it gets cleared.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology tests, vaccine response, FDA communications
REVIEW FLAG: False


#### 11. BioFire Predicate Use in COVID-19 Test Authorization

QA Block 11-1
CLARIFIED QUESTION: Is the BioFire de novo now the predicate for all COVID NAT tests or only for multi-plex respiratory panel type NAT tests that include COVID?
CLARIFIED ANSWER: The BioFire de novo is a predicate for all SARS tests, applicable to full and EUA authorizations. Currently, the BioFire is the only predicate for 510k submissions until more SARS-CoV-2 tests are authorized, but other high sensitivity RT-PCR tests may be comparators for clinical evaluation.
VERBATIM QUESTION: Is the BioFire de novo now the predicate for all COVID NAT tests or only for multi-plex respiratory panel type NAT tests that include COVID?
VERBATIM ANSWER: So I will let Toby fill in any gaps here but it's a predicate for all SARS tests. It can be used for full authorization comparisons and it also can be used for EUA authorization comparison. We are going to continue to be open for other comparators to be used for EUA authorizations as well as for full authorization because there may be not full availability for everybody to get a limited number of fully authorized tests until we get to that point. Once we get to that point where there is plenty of availability of fully authorized tests, you know, we will see what we do at that point. And I would just add that the - yes, until there are more 510ks authorized for SARS-CoV-2 whether as a single analyte or a multi-analyte test the BioFire is the only predicate for a 510k. But as Timothy said, we do, you know, we will consider other high sensitivity RT-PCR tests as the comparator for your clinical evaluation. But for the 510k, you know, paper submissions the BioFire would be the predicate of record.
SPEAKER QUESTION: Tim Snider
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: BioFire predicate, COVID diagnostics, 510k submissions
REVIEW FLAG: False

QA Block 11-2
CLARIFIED QUESTION: Can the BioFire predicate be used as a comparator for both emergency use authorization (EUA) and full regulatory submissions?
CLARIFIED ANSWER: The BioFire predicate can be used for both EUA and full regulatory authorization comparisons, but other comparators will also be considered, especially if fully authorized tests are not widely available.
VERBATIM QUESTION: Can the BioFire predicate be used as a comparator for both emergency use authorization (EUA) and full regulatory submissions?
VERBATIM ANSWER: It's a predicate for all SARS tests. It can be used for full authorization comparisons and it also can be used for EUA authorization comparison. We are going to continue to be open for other comparators to be used for EUA authorizations as well as for full authorization because there may be not full availability for everybody to get a limited number of fully authorized tests until we get to that point.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: BioFire predicate, EUA submissions, Regulatory submissions
REVIEW FLAG: False

QA Block 11-3
CLARIFIED QUESTION: What should test developers do if fully authorized tests are not readily available for comparison?
CLARIFIED ANSWER: The FDA is open to other comparators for EUA and full authorizations if fully authorized tests are not readily available, until availability improves.
VERBATIM QUESTION: What should test developers do if fully authorized tests are not readily available for comparison?
VERBATIM ANSWER: We are going to continue to be open for other comparators to be used for EUA authorizations as well as for full authorization because there may be not full availability for everybody to get a limited number of fully authorized tests until we get to that point. Once we get to that point where there is plenty of availability of fully authorized tests, you know, we will see what we do at that point.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA authorization, Full authorization, Comparator availability
REVIEW FLAG: False

QA Block 11-4
CLARIFIED QUESTION: Are high sensitivity RT-PCR tests acceptable as comparators for EUA submissions before more fully authorized predicates are available?
CLARIFIED ANSWER: High sensitivity RT-PCR tests can be considered as comparators for clinical evaluations in EUA submissions until more fully authorized predicates are available.
VERBATIM QUESTION: Are high sensitivity RT-PCR tests acceptable as comparators for EUA submissions before more fully authorized predicates are available?
VERBATIM ANSWER: But as Timothy said, we do, you know, we will consider other high sensitivity RT-PCR tests as the comparator for your clinical evaluation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: high sensitivity RT-PCR tests, EUA submissions, clinical evaluations
REVIEW FLAG: False

QA Block 11-5
CLARIFIED QUESTION: What is the process for listing the BioFire test as a predicate in a 510k submission?
CLARIFIED ANSWER: When submitting a 510k, you list the legally authorized BioFire test as the predicate to be applied.
VERBATIM QUESTION: What is the process for listing the BioFire test as a predicate in a 510k submission?
VERBATIM ANSWER: You know, that's a detail for those schooled in regulatory submissions about how you go about doing that but you can, you know, when you submit your 510k you list the legally authorized predicate that can be applied to the 510k.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: 510k submission, BioFire test, predicate listing
REVIEW FLAG: False


#### 12. Asymptomatic Serial Testing Criteria for Molecular Tests

QA Block 12-1
CLARIFIED QUESTION: Does the FDA have standard criteria for PPA and NPA specifically for molecular tests in the asymptomatic post-authorization clinical study?
CLARIFIED ANSWER: The FDA does not yet have a pre-set threshold for PPA and NPA in asymptomatic screening performance for molecular tests due to insufficient data. They ideally expect PAA above 80% for serial testing programs but are not making firm recommendations now.
VERBATIM QUESTION: Does the FDA have standard criteria for PPA and NPA specifically for molecular tests in the asymptomatic post-authorization clinical study?
VERBATIM ANSWER: So, you know, for molecular tests in symptomatic populations, you know, are above the 95% PPA in comparison to another EUAs authorized test. We would expect that, you know, a once weekly serial testing program with a molecular test would yield a very high PPA even in the asymptomatic population. Based on the recent data that has been a pre-print out, of a study that was sponsored by NIH and also other data that we have available. So we don't have a pre-set threshold for the asymptomatic screening performance because we just haven't seen enough data and we haven't seen other than the research study that was performed, we haven't seen to my knowledge a serial testing submission so we could see what the data looked like. So once we get experience on what tests generally are able to achieve and there may be differences between molecular and antigen tests for example because antigen tests are typically less sensitive than molecular tests it was difficult to set an expectation. But obviously ideally would like to see all serial testing programs in both symptomatic and asymptomatic be above an 80% PAA if possible but we are not setting a firm recommendation at this time.
SPEAKER QUESTION: Kristen Bancard
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: PPA and NPA criteria, asymptomatic screening, molecular tests
REVIEW FLAG: False

QA Block 12-2
CLARIFIED QUESTION: Does the FDA have any data on the effectiveness of weekly serial testing programs with molecular tests in asymptomatic populations?
CLARIFIED ANSWER: The FDA anticipates that weekly serial testing programs with molecular tests should yield high PPA in asymptomatic populations, based on recent pre-print data and other available information. However, there isn't enough data to set firm performance thresholds yet.
VERBATIM QUESTION: Does the FDA have any data on the effectiveness of weekly serial testing programs with molecular tests in asymptomatic populations?
VERBATIM ANSWER: We would expect that, you know, a once weekly serial testing program with a molecular test would yield a very high PPA even in the asymptomatic population. Based on the recent data that has been a pre-print out, of a study that was sponsored by NIH and also other data that we have available. So we don't have a pre-set threshold for the asymptomatic screening performance because we just haven't seen enough data and we haven't seen other than the research study that was performed, we haven't seen to my knowledge a serial testing submission so we could see what the data looked like.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serial testing, molecular tests, asymptomatic populations
REVIEW FLAG: False

QA Block 12-3
CLARIFIED QUESTION: Are there differences in expected performance standards for serial testing between molecular and antigen tests?
CLARIFIED ANSWER: The FDA acknowledges potential differences in serial testing performance standards between molecular and antigen tests, noting that antigen tests are typically less sensitive than molecular tests. However, no firm recommendations are set due to limited data.
VERBATIM QUESTION: Are there differences in expected performance standards for serial testing between molecular and antigen tests?
VERBATIM ANSWER: So, you know, for molecular tests in symptomatic populations, you know, are above the 95% PPA in comparison to another EUAs authorized test. We would expect that, you know, a once weekly serial testing program with a molecular test would yield a very high PPA even in the asymptomatic population. Based on the recent data that has been a pre-print out, of a study that was sponsored by NIH and also other data that we have available. So we don't have a pre-set threshold for the asymptomatic screening performance because we just haven't seen enough data and we haven't seen other than the research study that was performed, we haven't seen to my knowledge a serial testing submission so we could see what the data looked like. So once we get experience on what tests generally are able to achieve and there may be differences between molecular and antigen tests for example because antigen tests are typically less sensitive than molecular tests it was difficult to set an expectation. But obviously ideally would like to see all serial testing programs in both symptomatic and asymptomatic be above an 80% PAA if possible but we are not setting a firm recommendation at this time.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Differences between molecular and antigen tests, Serial testing performance, FDA performance standards
REVIEW FLAG: False

QA Block 12-4
CLARIFIED QUESTION: What threshold does the FDA expect for asymptomatic screening performance in the absence of a pre-set standard?
CLARIFIED ANSWER: The FDA has not set a pre-set threshold for asymptomatic screening performance due to limited data. Ideally, the FDA would like serial testing programs to achieve above 80% PAA, but this is not a firm recommendation currently.
VERBATIM QUESTION: What threshold does the FDA expect for asymptomatic screening performance in the absence of a pre-set standard?
VERBATIM ANSWER: We don't have a pre-set threshold for the asymptomatic screening performance because we just haven't seen enough data and we haven't seen other than the research study that was performed, we haven't seen to my knowledge a serial testing submission so we could see what the data looked like. So once we get experience on what tests generally are able to achieve and there may be differences between molecular and antigen tests for example because antigen tests are typically less sensitive than molecular tests it was difficult to set an expectation. But obviously ideally would like to see all serial testing programs in both symptomatic and asymptomatic be above an 80% PAA if possible but we are not setting a firm recommendation at this time.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: asymptomatic screening, performance thresholds, serial testing criteria
REVIEW FLAG: False

QA Block 12-5
CLARIFIED QUESTION: Does the FDA plan to set specific performance recommendations for serial testing in asymptomatic populations as more data becomes available?
CLARIFIED ANSWER: The FDA does not currently have specific performance recommendations for serial testing in asymptomatic populations due to limited data but would ideally like performances above 80% PAA.
VERBATIM QUESTION: Does the FDA plan to set specific performance recommendations for serial testing in asymptomatic populations as more data becomes available?
VERBATIM ANSWER: So we don't have a pre-set threshold for the asymptomatic screening performance because we just haven't seen enough data and we haven't seen other than the research study that was performed, we haven't seen to my knowledge a serial testing submission so we could see what the data looked like. So once we get experience on what tests generally are able to achieve and there may be differences between molecular and antigen tests for example because antigen tests are typically less sensitive than molecular tests it was difficult to set an expectation. But obviously ideally would like to see all serial testing programs in both symptomatic and asymptomatic be above an 80% PAA if possible but we are not setting a firm recommendation at this time.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serial testing, asymptomatic population, performance recommendations
REVIEW FLAG: False


#### 13. Adjusting Vaccination Exclusion Criteria in Molecular Trials

QA Block 13-1
CLARIFIED QUESTION: Would the preference be to remove the vaccination exclusion for all subjects or just individuals over the age of 65?
CLARIFIED ANSWER: FDA suggests submitting a proposal with trial details for review and plans to provide a specific response or clear answer in a future call.
VERBATIM QUESTION: Would the preference be to remove the vaccination exclusion for all subjects or just individuals over the age of 65?
VERBATIM ANSWER: Toby, I'm not sure that I'm prepared to answer that question. Maybe we write it down and respond unless you feel that you can handle that question today. No. I think I would suggest that you send in your proposal with additional details about your proposed trial and then we can respond specifically to your proposal. And, you know, I think we will take this back and discuss and hopefully provide a sort of a clear answer next week on the call.
SPEAKER QUESTION: Emily
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: vaccination exclusion, trial protocol, FDA guidance
REVIEW FLAG: False

QA Block 13-2
CLARIFIED QUESTION: What type of test is this?
CLARIFIED ANSWER: The test in question is a molecular test.
VERBATIM QUESTION: What type of test is this?
VERBATIM ANSWER: This is for a molecular test.
SPEAKER QUESTION: Tim Stenzel (FDA IVD Director)
SPEAKER ANSWER: Emily
TOPICS: test type, molecular test
REVIEW FLAG: False

QA Block 13-3
CLARIFIED QUESTION: What additional details should be included in the proposal when seeking feedback on a clinical trial for a molecular non-lab test?
CLARIFIED ANSWER: FDA recommends submitting your proposal with comprehensive details about the proposed trial to receive specific feedback.
VERBATIM QUESTION: What additional details should be included in the proposal when seeking feedback on a clinical trial for a molecular non-lab test?
VERBATIM ANSWER: No. I think I would suggest that you send in your proposal with additional details about your proposed trial and then we can respond specifically to your proposal.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: clinical trial proposals, molecular diagnostics, FDA feedback process
REVIEW FLAG: False

QA Block 13-4
CLARIFIED QUESTION: Is the FDA planning to provide further clarification on preferences about vaccination exclusions in future Town Hall meetings?
CLARIFIED ANSWER: The FDA plans to discuss the issue further and aims to provide a clearer answer in the next Town Hall meeting.
VERBATIM QUESTION: Is the FDA planning to provide further clarification on preferences about vaccination exclusions in future Town Hall meetings?
VERBATIM ANSWER: And, you know, I think we will take this back and discuss and hopefully provide a sort of a clear answer next week on the call.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: vaccination exclusion, future clarification
REVIEW FLAG: False


#### 14. Validation of Multiplex Tests for Flu and COVID

QA Block 14-1
CLARIFIED QUESTION: Is it okay to use inactivated virus of influenza A and B to make a contrived sample for the validation of a multiplex test for COVID and influenza?
CLARIFIED ANSWER: FDA prefers the use of archived samples to validate EUA panel tests for influenza A and B but acknowledges challenges in obtaining such samples. Contrived samples may still need further consideration, with post-authorization studies required.
VERBATIM QUESTION: Is it okay to use inactivated virus of influenza A and B to make a contrived sample for the validation of a multiplex test for COVID and influenza?
VERBATIM ANSWER: Yes, because there is already FDA cleared influenza tests on the market, we are wanting to make sure that performance of EUA panel tests that are new that we haven't seen before for flu A and B that they perform at an acceptable level and we are asking for archived samples. This is sort of the first time I have heard that archived samples are not available for flu A and B. You can always send an email with a pre-EUA to our template's box. But until we know what flu A and B banks are depleted for clinical samples, we would still like to see archived samples prior to EUA authorization. And then as we discussed we would ask to see a prospective study post- authorization to be able to be considered for EUA authorization. So you explain your challenges in trying to obtain these archived samples. But again this is an area where we have already cleared flu A and B and they are available in the market and so we are being cautious.
SPEAKER QUESTION: Perchim Greg
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: use of contrived samples, validation of multiplex tests, FDA authorization requirements
REVIEW FLAG: False

QA Block 14-2
CLARIFIED QUESTION: What should developers do if archived clinical samples for influenza A and B are unavailable?
CLARIFIED ANSWER: FDA suggests sending an email with a pre-EUA to their template's email box to explain challenges in obtaining archived samples. However, FDA still prefers archived samples for authorization, and a prospective study may be required post-authorization.
VERBATIM QUESTION: What should developers do if archived clinical samples for influenza A and B are unavailable?
VERBATIM ANSWER: This is sort of the first time I have heard that archived samples are not available for flu A and B. You can always send an email with a pre-EUA to our template's box. But until we know what flu A and B banks are depleted for clinical samples, we would still like to see archived samples prior to EUA authorization. And then as we discussed we would ask to see a prospective study post- authorization to be able to be considered for EUA authorization.
SPEAKER QUESTION: Perchim Greg
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Archived samples for flu A and B, EUA authorization requirements
REVIEW FLAG: False

QA Block 14-3
CLARIFIED QUESTION: Is it permitted to proceed with a prospective study as part of the validation process for multiplex EUA authorization tests?
CLARIFIED ANSWER: A prospective study is required post-authorization for EUA authorization consideration.
VERBATIM QUESTION: Is it permitted to proceed with a prospective study as part of the validation process for multiplex EUA authorization tests?
VERBATIM ANSWER: And then as we discussed we would ask to see a prospective study post- authorization to be able to be considered for EUA authorization.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: prospective study, EUA authorization, multiplex test validation
REVIEW FLAG: False

QA Block 14-4
CLARIFIED QUESTION: Can developers submit a pre-EUA email explaining challenges in obtaining clinical samples for FDA consideration?
CLARIFIED ANSWER: Developers can submit a pre-EUA email outlining challenges in obtaining clinical samples, but FDA still prefers archived samples prior to EUA authorization and may require a post-authorization prospective study.
VERBATIM QUESTION: Can developers submit a pre-EUA email explaining challenges in obtaining clinical samples for FDA consideration?
VERBATIM ANSWER: You can always send an email with a pre-EUA to our template's box. But until we know what flu A and B banks are depleted for clinical samples, we would still like to see archived samples prior to EUA authorization. And then as we discussed we would ask to see a prospective study post- authorization to be able to be considered for EUA authorization. So you explain your challenges in trying to obtain these archived samples.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA submission, clinical sample challenges, EUA validation
REVIEW FLAG: False

QA Block 14-5
CLARIFIED QUESTION: Are there alternative pathways for validation if influenza A and B sample banks are depleted?
CLARIFIED ANSWER: FDA requires archived samples for influenza A and B prior to EUA authorization, but if these are depleted, a prospective study post-authorization might be considered.
VERBATIM QUESTION: Are there alternative pathways for validation if influenza A and B sample banks are depleted?
VERBATIM ANSWER: But until we know what flu A and B banks are depleted for clinical samples, we would still like to see archived samples prior to EUA authorization. And then as we discussed we would ask to see a prospective study post- authorization to be able to be considered for EUA authorization.
SPEAKER QUESTION: Perchim Greg
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA authorization, influenza A and B validation, sample availability
REVIEW FLAG: False

QA Block 14-6
CLARIFIED QUESTION: What is the FDA's position on using contrived samples for non-SARS respiratory viruses in tests with new EUA applications?
CLARIFIED ANSWER: The FDA prefers archived samples for validating new EUA panel tests for influenza A and B since several tests for flu A and B are already cleared. Until clinical sample availability issues are confirmed, archived samples remain required before EUA authorization. A prospective study would also be required post-authorization.
VERBATIM QUESTION: What is the FDA's position on using contrived samples for non-SARS respiratory viruses in tests with new EUA applications?
VERBATIM ANSWER: Yes, because there is already FDA cleared influenza tests on the market, we are wanting to make sure that performance of EUA panel tests that are new that we haven't seen before for flu A and B that they perform at an acceptable level and we are asking for archived samples. This is sort of the first time I have heard that archived samples are not available for flu A and B. You can always send an email with a pre-EUA to our template's box. But until we know what flu A and B banks are depleted for clinical samples, we would still like to see archived samples prior to EUA authorization. And then as we discussed we would ask to see a prospective study post-authorization to be able to be considered for EUA authorization. So you explain your challenges in trying to obtain these archived samples. But again this is an area where we have already cleared flu A and B and they are available in the market and so we are being cautious.
SPEAKER QUESTION: Perchim Greg
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA application, contrived samples, non-SARS respiratory viruses
REVIEW FLAG: False


#### 15. Stability Testing Requirements for EUA Authorization and Shipping

QA Block 15-1
CLARIFIED QUESTION: For an EUA submission, does the FDA require a simulated 'worst-case shake and bake' scenario for shipping and handling stability testing?
CLARIFIED ANSWER: FDA does not require simulated 'worst-case shake and bake' testing for EUA submissions but expects shipping stability studies addressing temperature extremes, such as high heat or freezing conditions.
VERBATIM QUESTION: For an EUA submission, does the FDA require a simulated 'worst-case shake and bake' scenario for shipping and handling stability testing?
VERBATIM ANSWER: Toby, I'm not sure how much the templates go into detail on this. But we are satisfied with an in-lab stability testing, looking at for EUA authorization looking at temperature stability. And so now since we can expect that this pandemic will go year-round or the testing at least for SARS will go year-round going forward -- we expect to see potential extremes or heat or high temperatures and the extremes of frozen temperatures on shipping stability.
SPEAKER QUESTION: Annie Wright
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA shipping stability, temperature extremes
REVIEW FLAG: False

QA Block 15-2
CLARIFIED QUESTION: Is it acceptable to submit shipping studies that only show the transportation stability of the device without simulated 'shaking and baking'?
CLARIFIED ANSWER: For EUA authorization, FDA allows shipping studies focusing on temperature extremes without requiring simulated 'shaking and baking.'
VERBATIM QUESTION: Is it acceptable to submit shipping studies that only show the transportation stability of the device without simulated 'shaking and baking'?
VERBATIM ANSWER: Yes. So for full authorization we would potentially look at some things like drops and things like that but have since pulled that back for EUAs since the bar can be lower for EUA authorization. So I believe but double check that it's just the temperature extremes on shipping.
SPEAKER QUESTION: Annie Wright
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA shipping studies, temperature stability, FDA requirements
REVIEW FLAG: False

QA Block 15-3
CLARIFIED QUESTION: For extreme temperatures, does the FDA expect such data to be included in the EUA submission, or can it be submitted later as part of an ongoing study?
CLARIFIED ANSWER: For home collection, FDA requires the shipping stability study to be reviewed prior to authorization. If a previously authorized reference, like the Gates collection study, applies, submission may rely on it. For unique proprietary devices, new stability studies are required.
VERBATIM QUESTION: For extreme temperatures, does the FDA expect such data to be included in the EUA submission, or can it be submitted later as part of an ongoing study?
VERBATIM ANSWER: So for a home collection situation we are asking to review that shipping stability study prior to authorization. If you were already using something for which we have authorized and managed for a right of reference such as the Gates collection study. You could potentially if you use the sort of exact same things you can potentially fall under that right of reference that gates has offered and you can ask about that in the submission. But if you have a specifically proprietary unique device then those stability studies would need to be repeated.
SPEAKER QUESTION: Annie Wright
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Shipping stability studies, EUA submission requirements, Home collection kits
REVIEW FLAG: False

QA Block 15-5
CLARIFIED QUESTION: If using a previously authorized collection method, can a submission fall under the right of reference, or does stability testing need to be repeated for proprietary unique devices?
CLARIFIED ANSWER: The FDA allows using the right of reference for submissions if the previously authorized method, such as the Gates collection study, is used exactly. However, for proprietary unique devices, stability testing must be repeated.
VERBATIM QUESTION: If using a previously authorized collection method, can a submission fall under the right of reference, or does stability testing need to be repeated for proprietary unique devices?
VERBATIM ANSWER: So for a home collection situation we are asking to review that shipping stability study prior to authorization. If you were already using something for which we have authorized and managed for a right of reference such as the Gates collection study. You could potentially if you use the sort of exact same things you can potentially fall under that right of reference that gates has offered and you can ask about that in the submission. But if you have a specifically proprietary unique device then those stability studies would need to be repeated.
SPEAKER QUESTION: Annie Wright
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Right of reference, Stability testing, Home collection devices
REVIEW FLAG: False

QA Block 15-6
CLARIFIED QUESTION: Can real-time stability data be submitted post-EUA authorization, or is pre-authorization accelerated stability data mandatory for collection kits?
CLARIFIED ANSWER: Pre-authorization accelerated stability data is mandatory for collection kits, including shipping and collection capability testing. Real-time data applies only post-authorization but not for shipping.
VERBATIM QUESTION: Can real-time stability data be submitted post-EUA authorization, or is pre-authorization accelerated stability data mandatory for collection kits?
VERBATIM ANSWER: No. Actual real-time data - so I was talking about two different things. Real- time is for the collection capability testing, not shipping. And for that we would want to see accelerated stability testing of your collection kit. And then we also want to see the shipping stability to make the authorization for - as part of the authorization required recommendations for a home collection kit.
SPEAKER QUESTION: Annie Wright
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: stability data requirements, EUA authorization for collection kits
REVIEW FLAG: False

QA Block 15-8
CLARIFIED QUESTION: If a collection kit uses widely marketed standard devices, like a nasal swab, does it still need specific stability data to be provided?
CLARIFIED ANSWER: For widely marketed standard devices, like a nasal swab, additional stability data is not typically required, unless the device is proprietary or unique.
VERBATIM QUESTION: If a collection kit uses widely marketed standard devices, like a nasal swab, does it still need specific stability data to be provided?
VERBATIM ANSWER: Right. If it's some, you know, proprietary collection device we would expect to see information on the specific collection device including some of the stability data if you are, you know, simply using previously, you know, widely marketed, you know, a standard nasal swab and things like that then we are not likely to have additional questions.
SPEAKER QUESTION: Annie Wright
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: stability data, standard devices, nasal swabs
REVIEW FLAG: False

QA Block 15-9
CLARIFIED QUESTION: What types of stability testing are considered sufficient for EUA authorization of a COVID-19 diagnostic collection kit?
CLARIFIED ANSWER: The FDA requires in-lab stability testing for EUA authorization, focusing on temperature stability, and shipping stability testing for extreme heat and frozen conditions. Additional requirements like drop-tests are needed for full authorization, but not for EUA.
VERBATIM QUESTION: What types of stability testing are considered sufficient for EUA authorization of a COVID-19 diagnostic collection kit?
VERBATIM ANSWER: We are satisfied with an in-lab stability testing, looking at for EUA authorization looking at temperature stability. And so now since we can expect that this pandemic will go year-round or the testing at least for SARS will go year-round going forward -- we expect to see potential extremes or heat or high temperatures and the extremes of frozen temperatures on shipping stability. So for full authorization we would potentially look at some things like drops and things like that but have since pulled that back for EUAs since the bar can be lower for EUA authorization. So I believe but double check that it's just the temperature extremes on shipping. And for the potentially extreme time for any return, we also ask for stability testing on any home collection device to make sure once it enters into commerce that it has an expiration date and that we know what that is.
SPEAKER QUESTION: Annie Wright
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA stability testing, Temperature stability, Shipping stability
REVIEW FLAG: False

QA Block 15-10
CLARIFIED QUESTION: Does the FDA require stability testing data for the approval of home collection kits on return shipping conditions?
CLARIFIED ANSWER: The FDA requires a shipping stability study to be reviewed prior to authorization for home collection kits. If a previously authorized device, like the Gates collection study, is used, the study may not need to be repeated. However, proprietary unique devices require new stability testing.
VERBATIM QUESTION: Does the FDA require stability testing data for the approval of home collection kits on return shipping conditions?
VERBATIM ANSWER: So for a home collection situation we are asking to review that shipping stability study prior to authorization. If you were already using something for which we have authorized and managed for a right of reference such as the Gates collection study. You could potentially if you use the sort of exact same things you can potentially fall under that right of reference that gates has offered and you can ask about that in the submission. But if you have a specifically proprietary unique device then those stability studies would need to be repeated.
SPEAKER QUESTION: Annie Wright
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home collection kits, stability testing, FDA approval
REVIEW FLAG: False

QA Block 15-11
CLARIFIED QUESTION: What are the FDA's expectations for documenting the expiration date for home collection devices during EUA authorization?
CLARIFIED ANSWER: The FDA requires stability testing for home collection devices to ensure they have a documented expiration date when entering commerce.
VERBATIM QUESTION: What are the FDA's expectations for documenting the expiration date for home collection devices during EUA authorization?
VERBATIM ANSWER: And for the potentially extreme time for any return, we also ask for stability testing on any home collection device to make sure once it enters into commerce that it has an expiration date and that we know what that is.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Home collection devices, Expiration date, EUA authorization
REVIEW FLAG: False

QA Block 15-12
CLARIFIED QUESTION: What are the requirements for real-time stability testing versus accelerated stability testing for collection kits?
CLARIFIED ANSWER: Real-time data is required for collection capability testing, while accelerated stability testing is needed for the collection kit itself. Shipping stability is also required for home collection kit authorization.
VERBATIM QUESTION: What are the requirements for real-time stability testing versus accelerated stability testing for collection kits?
VERBATIM ANSWER: No. Actual real-time data - so I was talking about two different things. Real- time is for the collection capability testing, not shipping. And for that we would want to see accelerated stability testing of your collection kit. And then we also want to see the shipping stability to make the authorization for - as part of the authorization required recommendations for a home collection kit.
SPEAKER QUESTION: Annie Wright
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: real-time stability testing, accelerated stability testing, collection kit authorization
REVIEW FLAG: False

QA Block 15-13
CLARIFIED QUESTION: Does the FDA require additional stability data for proprietary collection devices compared to standard, widely marketed devices?
CLARIFIED ANSWER: FDA expects additional stability data for proprietary collection devices but is less likely to require this for standard, widely marketed devices like nasal swabs.
VERBATIM QUESTION: Does the FDA require additional stability data for proprietary collection devices compared to standard, widely marketed devices?
VERBATIM ANSWER: Right. If it's some, you know, proprietary collection device we would expect to see information on the specific collection device including some of the stability data if you are, you know, simply using previously, you know, widely marketed, you know, a standard nasal swab and things like that then we are not likely to have additional questions.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Stability testing, Proprietary devices, Standard devices
REVIEW FLAG: False

QA Block 15-14
CLARIFIED QUESTION: If a collection kit is intended to support both SARS and SARS plus a panel, will it be treated as a higher regulatory burden device under EUA?
CLARIFIED ANSWER: The FDA would treat collection kits that make claims for use with SARS or SARS plus a panel as devices. Regulatory requirements, including stability data, would be reviewed, especially if the collection kit is proprietary.
VERBATIM QUESTION: If a collection kit is intended to support both SARS and SARS plus a panel, will it be treated as a higher regulatory burden device under EUA?
VERBATIM ANSWER: So for professional use these are collection kits. Toby, you can help me out here. But if a kit makes a claim about use of the collection kit in for SARS or SARS plus a panel we would treat that as a device and we would ask for and obviously to be shipped and so we would look at the same sort of things there. Toby, did I get that right?
SPEAKER QUESTION: Annie Wright
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA requirements, Collection kit claims, Regulatory review
REVIEW FLAG: False


#### 16. Clarifying Age Requirements for OTC Testing Studies

QA Block 16-1
CLARIFIED QUESTION: Can you confirm that the age range for an OTC designation is 2 to 65 years, or is 3 to 65 years adequate?
CLARIFIED ANSWER: FDA confirmed that the age range for an OTC designation is 2 to 65 years, not 3 to 65 years. For self-collection, individuals aged 14 and above can self-collect, while those under 14 require collection by a parent, guardian, or adult.
VERBATIM QUESTION: Can you confirm that the age range for an OTC designation is 2 to 65 years, or is 3 to 65 years adequate?
VERBATIM ANSWER: Thanks for pointing that potential typo here. Yes, the intended use population and, you know, we would like to see data for age range is 2 to 65 I believe, not three. And for self-collection in that population we typically say age 14 and above can self-collect and below that a parent, guardian, adult would collect.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: OTC designation age range, self-collection age guidelines
REVIEW FLAG: False

QA Block 16-3
CLARIFIED QUESTION: Are there specific data requirements for the self-collection age group of 14 and above?
CLARIFIED ANSWER: The FDA requires data for self-collection starting at age 14 and above. Below that age, sample collection must be done by a parent, guardian, or adult.
VERBATIM QUESTION: Are there specific data requirements for the self-collection age group of 14 and above?
VERBATIM ANSWER: Yes, the intended use population and, you know, we would like to see data for age range is 2 to 65 I believe, not three. And for self-collection in that population we typically say age 14 and above can self-collect and below that a parent, guardian, adult would collect.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: self-collection age requirements, data for age groups
REVIEW FLAG: False

QA Block 16-4
CLARIFIED QUESTION: What are the considerations for including age groups over 65 in study populations?
CLARIFIED ANSWER: FDA recommends including participants over age 65 in study populations to capture potential issues, ensuring a representative range across age groups.
VERBATIM QUESTION: What are the considerations for including age groups over 65 in study populations?
VERBATIM ANSWER: So, you know, so what we want to see is that sort of age groups are included. So I would like to see folk's aged 2 to 14, you know, collected by a parent, guardian or an adult. And then above 14 to above 65, you know, we would like to see, you know, obviously there is different potential issues in some groups so I would to see a good range so, you know, include those who are 65 plus and typically, you know, those we enrolled in age 14 to 65 is in typically depending on how many enrollees you have in your study you are going to see a good range on that. But make sure you have got representatives of those below 14 and those above 65 and then probably have plenty between the two.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: study population, age range, testing guidelines
REVIEW FLAG: False

QA Block 16-5
CLARIFIED QUESTION: How should developers ensure a representative distribution of study subjects across all age groups?
CLARIFIED ANSWER: Developers should include participants aged 2 to 14, collected by a guardian or adult, and ensure representation above 65 years. Adolescents aged 14 to adults aged 65 should be well-distributed, balancing all age ranges.
VERBATIM QUESTION: How should developers ensure a representative distribution of study subjects across all age groups?
VERBATIM ANSWER: So, you know, so what we want to see is that sort of age groups are included. So I would like to see folk's aged 2 to 14, you know, collected by a parent, guardian ort an adult. And then above 14 to above 65, you know, we would like to see, you know, obviously there is different potential issues in some groups so I would to see a good range so, you know, include those who are 65 plus and typically, you know, those we enrolled in age 14 to 65 is in typically depending on how many enrollees you have in your study you are going to see a good range on that. But make sure you have got representatives of those below 14 and those above 65 and then probably have plenty between the two.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Study subject distribution, Age group representation, Diagnostic testing
REVIEW FLAG: False

QA Block 16-6
CLARIFIED QUESTION: Are there guidelines for parent or guardian sample collection for children under 14?
CLARIFIED ANSWER: FDA guidelines specify that for children under 14, a parent, guardian, or adult should collect the sample, while individuals aged 14 and above can self-collect.
VERBATIM QUESTION: Are there guidelines for parent or guardian sample collection for children under 14?
VERBATIM ANSWER: Thanks for pointing that potential typo here. Yes, the intended use population and, you know, we would like to see data for age range is 2 to 65 I believe, not three. And for self-collection in that population we typically say age 14 and above can self-collect and below that a parent, guardian, adult would collect.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sample collection guidelines, children under 14, age-specific requirements
REVIEW FLAG: False


#### 17. Monitoring Plans for Emerging Viral Mutations in Diagnostic Testing

QA Block 17-1
CLARIFIED QUESTION: Is the performance evaluation, specifically the emerging viral mutation monitoring plan, expected for manufacturers who already have an EUA?
CLARIFIED ANSWER: FDA requires all test developers, regardless of EUA status, to have a viral mutation monitoring plan, but manufacturers with existing EUAs are not required to submit the plan unless submitting a new application.
VERBATIM QUESTION: Is the performance evaluation, specifically the emerging viral mutation monitoring plan, expected for manufacturers who already have an EUA?
VERBATIM ANSWER: Okay. So it is something we have asked all test developers whether they have been EUA authorized or not to do, to have a monitoring plan in place. For those who are under review now or submitting in the future, we would want to see that plan. We are not asking manufacturers who have already been authorized to come back in with a plan submission but to have a plan in place and to act upon it.
SPEAKER QUESTION: Jackie Chin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Emerging viral mutation monitoring, EUA requirements, Performance evaluation
REVIEW FLAG: False

QA Block 17-2
CLARIFIED QUESTION: Can you share examples of how manufacturers address monitoring and dealing with new and emerging viral mutations for serology or neutralizing antibody tests?
CLARIFIED ANSWER: FDA expects all test manufacturers, regardless of EUA status, to have a mutation monitoring plan. For molecular tests, monitoring involves assessing primers, probes, and cycling parameters. For serology tests, the antigen sequence must be monitored for changes in the SARS database. Similarly, antigen test developers must map antibody-virus binding and review antigen sequences.
VERBATIM QUESTION: Can you share examples of how manufacturers address monitoring and dealing with new and emerging viral mutations for serology or neutralizing antibody tests?
VERBATIM ANSWER: Okay. So it is something we have asked all test developers whether they have been EUA authorized or not to do, to have a monitoring plan in place. For those who are under review now or submitting in the future, we would want to see that plan. We are not asking manufacturers who have already been authorized to come back in with a plan submission but to have a plan in place and to act upon it. But for those that are a new submissions we will be asking about that for all assay types and, you know, knowledge of your specific test is needed to address any potential issues. Molecular tests are relatively straight forward in that, you know, the sequence of the primers and probes, you can do calculations around melting temperatures and know what your cycling parameters are or your isothermal parameters are. And determine with some modeling, simple modeling, whether or not your assay potentially could be affected. Serology tests are more challenging. We are all current in serology testing in review, we are now asking for the antigen sequence that you are using and we are logging that into our database. Obviously it's an amino acid sequence and so we would be scanning the nucleic acid sequence database for SARS for any amino acid changes within the antigen portion of the serology tests and we would ask developers to do the same for antibody tests - for serology tests. For antigen tests there is a different pathway. Developers would need to understand the characteristics of the antibodies that they use in their antigen test and know the map of, you know, the antibody binding to the virus which is specific for every type of antibody that's monoclonal. Polyclonal will have, you know, different things to look for. But and there it may depend on, a polyclonal antibody, it may depend on what the antigen was used and the sequence of that antigen to raise the antibodies for that antigen test. So every test developer has some different things that they can do and we are just asking that they come in with a plan. It all starts with the specific knowledge of your own test and examination of sequences in the US circulating sequence database.
SPEAKER QUESTION: Jackie Chin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Mutation monitoring in tests, FDA expectations on plans, Serology and molecular testing
REVIEW FLAG: False

QA Block 17-3
CLARIFIED QUESTION: What specific elements should be included in a monitoring plan for emerging viral mutations?
CLARIFIED ANSWER: Test developers should include elements such as modeling to assess assay performance, analysis of primers, probes, and antigen sequences, and logging antigen sequences in databases. Developers should ensure knowledge of their specific tests and monitor circulating virus sequences.
VERBATIM QUESTION: What specific elements should be included in a monitoring plan for emerging viral mutations?
VERBATIM ANSWER: It is something we have asked all test developers whether they have been EUA authorized or not to do, to have a monitoring plan in place. For those who are under review now or submitting in the future, we would want to see that plan. We are not asking manufacturers who have already been authorized to come back in with a plan submission but to have a plan in place and to act upon it. But for those that are a new submissions we will be asking about that for all assay types and, you know, knowledge of your specific test is needed to address any potential issues. Molecular tests are relatively straight forward in that, you know, the sequence of the primers and probes, you can do calculations around melting temperatures and know what your cycling parameters are or your isothermal parameters are. And determine with some modeling, simple modeling, whether or not your assay potentially could be affected. Serology tests are more challenging. We are all current in serology testing in review, we are now asking for the antigen sequence that you are using and we are logging that into our database. Obviously it's an amino acid sequence and so we would be scanning the nucleic acid sequence database for SARS for any amino acid changes within the antigen portion of the serology tests and we would ask developers to do the same for antibody tests - for serology tests. For antigen tests there is a different pathway. Developers would need to understand the characteristics of the antibodies that they use in their antigen test and know the map of, you know, the antibody binding to the virus which is specific for every type of antibody that's monoclonal. Polyclonal will have, you know, different things to look for. But and there it may depend on, a polyclonal antibody, it may depend on what the antigen was used and the sequence of that antigen to raise the antibodies for that antigen test. So every test developer has some different things that they can do and we are just asking that they come in with a plan. It all starts with the specific knowledge of your own test and examination of sequences in the US circulating sequence database.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Monitoring plan elements, Addressing viral mutations, Test-specific requirements
REVIEW FLAG: False

QA Block 17-4
CLARIFIED QUESTION: For newly submitted assays, what level of detail does the FDA expect developers to include regarding mutation monitoring?
CLARIFIED ANSWER: For newly submitted assays, the FDA expects developers to submit a mutation monitoring plan. Developers should use their test's specific knowledge to assess potential issues. For molecular tests, providing details like primer/probe sequences and modeling data is crucial. Serology tests require antigen sequences, which are logged in FDA's database and monitored for amino acid changes.
VERBATIM QUESTION: For newly submitted assays, what level of detail does the FDA expect developers to include regarding mutation monitoring?
VERBATIM ANSWER: For those who are under review now or submitting in the future, we would want to see that plan. We are not asking manufacturers who have already been authorized to come back in with a plan submission but to have a plan in place and to act upon it. But for those that are a new submissions we will be asking about that for all assay types and, you know, knowledge of your specific test is needed to address any potential issues. Molecular tests are relatively straight forward in that, you know, the sequence of the primers and probes, you can do calculations around melting temperatures and know what your cycling parameters are or your isothermal parameters are. And determine with some modeling, simple modeling, whether or not your assay potentially could be affected. Serology tests are more challenging. We are all current in serology testing in review, we are now asking for the antigen sequence that you are using and we are logging that into our database. Obviously it's an amino acid sequence and so we would be scanning the nucleic acid sequence database for SARS for any amino acid changes within the antigen portion of the serology tests and we would ask developers to do the same for antibody tests - for serology tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Mutation monitoring, Assay submissions, FDA expectations
REVIEW FLAG: False

QA Block 17-5
CLARIFIED QUESTION: How can molecular test developers determine if viral mutations will affect primer or probe performance through modeling?
CLARIFIED ANSWER: Molecular test developers can determine if viral mutations will affect primer or probe performance by calculating melting temperatures, considering cycling or isothermal parameters, and performing simple modeling.
VERBATIM QUESTION: How can molecular test developers determine if viral mutations will affect primer or probe performance through modeling?
VERBATIM ANSWER: Molecular tests are relatively straight forward in that, you know, the sequence of the primers and probes, you can do calculations around melting temperatures and know what your cycling parameters are or your isothermal parameters are. And determine with some modeling, simple modeling, whether or not your assay potentially could be affected.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Molecular test primer/probe performance, Viral mutations, Modeling for diagnostics
REVIEW FLAG: False

QA Block 17-6
CLARIFIED QUESTION: What are the FDA's expectations for developers regarding the sequence analysis for SARS-CoV-2 in serology tests?
CLARIFIED ANSWER: The FDA expects developers of serology tests to provide the antigen sequence used, which will be logged in the FDA's database. Developers should also monitor for amino acid changes in SARS-CoV-2 sequences corresponding to the antigen portion of their tests, using the US circulating sequence database.
VERBATIM QUESTION: What are the FDA's expectations for developers regarding the sequence analysis for SARS-CoV-2 in serology tests?
VERBATIM ANSWER: We are all current in serology testing in review, we are now asking for the antigen sequence that you are using and we are logging that into our database. Obviously it's an amino acid sequence and so we would be scanning the nucleic acid sequence database for SARS for any amino acid changes within the antigen portion of the serology tests and we would ask developers to do the same for antibody tests - for serology tests. It all starts with the specific knowledge of your own test and examination of sequences in the US circulating sequence database.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA expectations, serology test sequence analysis, monitoring amino acid changes
REVIEW FLAG: False

QA Block 17-7
CLARIFIED QUESTION: What information should antigen test developers provide about antibodies used in their tests?
CLARIFIED ANSWER: FDA expects antigen test developers to understand the characteristics of the antibodies used in their tests, including binding specificity for monoclonal antibodies and antigen sequence information for polyclonal antibodies. Developers should submit a plan that includes considerations based on their test's specific attributes.
VERBATIM QUESTION: What information should antigen test developers provide about antibodies used in their tests?
VERBATIM ANSWER: Developers would need to understand the characteristics of the antibodies that they use in their antigen test and know the map of, you know, the antibody binding to the virus which is specific for every type of antibody that's monoclonal. Polyclonal will have, you know, different things to look for. But and there it may depend on, a polyclonal antibody, it may depend on what the antigen was used and the sequence of that antigen to raise the antibodies for that antigen test. So every test developer has some different things that they can do and we are just asking that they come in with a plan.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen test development, Antibody characterization, FDA submission requirements
REVIEW FLAG: False

QA Block 17-8
CLARIFIED QUESTION: How should polyclonal antibody developers account for antigen sequences in their monitoring plans?
CLARIFIED ANSWER: Polyclonal antibody developers should focus on the antigen used and its sequence to raise antibodies for the test, have a clear monitoring plan, and analyze sequences in the US circulating sequence database.
VERBATIM QUESTION: How should polyclonal antibody developers account for antigen sequences in their monitoring plans?
VERBATIM ANSWER: Polyclonal will have, you know, different things to look for. But and there it may depend on, a polyclonal antibody, it may depend on what the antigen was used and the sequence of that antigen to raise the antibodies for that antigen test. So every test developer has some different things that they can do and we are just asking that they come in with a plan. It all starts with the specific knowledge of your own test and examination of sequences in the US circulating sequence database.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Polyclonal antibodies, Antigen sequence monitoring, Diagnostic test planning
REVIEW FLAG: False

QA Block 17-9
CLARIFIED QUESTION: What resources or tools does the FDA recommend for examining US circulating sequence databases?
CLARIFIED ANSWER: FDA recommends that test developers start with specific knowledge of their test and examine sequences in the US circulating sequence database.
VERBATIM QUESTION: What resources or tools does the FDA recommend for examining US circulating sequence databases?
VERBATIM ANSWER: It all starts with the specific knowledge of your own test and examination of sequences in the US circulating sequence database.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: US circulating sequence database, resources for test developers, FDA recommendations
REVIEW FLAG: False

### removed qa blocks
QA Block 1-10
CLARIFIED QUESTION: What recommendations does the FDA have for developers submitting supplemental EUA requests for serial testing claims?
CLARIFIED ANSWER: Developers submitting supplemental EUA requests for serial testing claims do not generally need additional pre-authorization data. FDA recommends including the requested indication, serial testing interval, and proposed post-authorization validation study in the submission.
VERBATIM QUESTION: What recommendations does the FDA have for developers submitting supplemental EUA requests for serial testing claims?
VERBATIM ANSWER: If you are interested in the serial screening claim as outlined in the supplemental EUA template, you likely don't need any additional pre-authorization data. In that case we recommend that you submit a supplemental EUA request with your requested indication including the serial testing interval and your proposed post authorization validation study.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Supplemental EUA requests, Serial testing claims, FDA guidance
REVIEW FLAG: False

QA Block 1-12
CLARIFIED QUESTION: Can serial testing be used for symptomatic individuals if an antigen test does not meet 80% sensitivity thresholds?
CLARIFIED ANSWER: Serial testing may support authorization for antigen tests with sensitivity under 80%, but clinical evaluation in asymptomatic individuals must be completed before authorization. Validation criteria shifting to post-authorization does not apply to such tests.
VERBATIM QUESTION: Can serial testing be used for symptomatic individuals if an antigen test does not meet 80% sensitivity thresholds?
VERBATIM ANSWER: Regarding serial testing we also received a question about antigen tests and whether the serial testing approach would be acceptable if the antigen assay does not reach the 80% sensitivity in symptomatic individuals. We do discuss in the antigen template for test developers that strategies for serial testing with less sensitive tests such as the PPO less than 80% may be able to support authorization. But in those cases we would expect the clinical evaluation in an asymptomatic population to be completed prior to authorization of a screening claim. The shift of the validation to post authorization discussed in the supplemental template is not applicable for tests with sensitivity below 80% in symptomatic subjects.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Serial testing, Antigen test sensitivity, Test authorization
REVIEW FLAG: False

QA Block 2-3
CLARIFIED QUESTION: What PPA do you recommend for OTC antigen tests in the non-lab template compared to the comparator test?
CLARIFIED ANSWER: The FDA recommends a minimum of 90% PPA for OTC tests in the non-lab antigen template compared to the comparator test, and 80% PPA for serial testing claims as per the new supplemental template.
VERBATIM QUESTION: What PPA do you recommend for OTC antigen tests in the non-lab template compared to the comparator test?
VERBATIM ANSWER: For an EUA review, it is different than a 510k review. So for an EUA, it is not a substantial equivalence determination so there is no predicate. But we do often, you know, ask for a comparator test to be used in your clinical evaluation so I think that's likely what this question is referring to. And we do recommend for OTC tests in the antigen the - sorry, the non-lab template, we do recommend a minimum of 90% PPA for OTC tests as compared to the comparator test. And in the new supplemental template issued last week we recommend a minimum of 80% PPA for serial testing claims.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: OTC antigen test PPA, non-lab template, serial testing claims
REVIEW FLAG: False

QA Block 2-6
CLARIFIED QUESTION: What are the requirements for the comparator test when used in EUA evaluations?
CLARIFIED ANSWER: The comparator test for EUA evaluations can be a recently authorized molecular test or EUA-authorized high-sensitivity molecular test with an extraction step.
VERBATIM QUESTION: What are the requirements for the comparator test when used in EUA evaluations?
VERBATIM ANSWER: The comparator test can be, you know, the recently granted molecular test and any subsequent ones coming in for full authorization could use that test. But then if you use the EUA authorized comparators as long as they are high sensitivity molecular tests with an extraction step.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA comparator tests, Molecular test requirements
REVIEW FLAG: False

QA Block 4-4
CLARIFIED QUESTION: Does the BioFire de novo authorization affect the EUA status of other developers' tests?
CLARIFIED ANSWER: The BioFire de novo authorization does not affect EUAs for other developers' tests. It only impacts BioFire's EUA for the identical test, which was revoked when the de novo was granted.
VERBATIM QUESTION: Does the BioFire de novo authorization affect the EUA status of other developers' tests?
VERBATIM ANSWER: The BioFire de novo does not impact any EUAs other than their own for that identical test which we revoked concurrent to granting the de novo for the same test. BioFire's other EUAs including the point of care test as well as EUAs for other - where other developers were not impacted.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: BioFire de novo authorization, EUA impact, COVID-19 diagnostic tests
REVIEW FLAG: False

QA Block 5-13
CLARIFIED QUESTION: What performance requirements must be met for serial screening claims to use post-authorization asymptomatic data collection?
CLARIFIED ANSWER: The FDA may allow serial screening claims with post-authorization asymptomatic data collection if the test demonstrates a positive percent agreement (PPA) of at least 80% in symptomatic individuals.
VERBATIM QUESTION: What performance requirements must be met for serial screening claims to use post-authorization asymptomatic data collection?
VERBATIM ANSWER: But in the case of serial screening per the supplemental template we will consider authorizing that claim with a post-authorization condition to establish performance with asymptomatic individuals when your PPA is at least 80% in symptomatic individuals.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: serial screening claims, asymptomatic data collection, performance requirements
REVIEW FLAG: False

QA Block 5-14
CLARIFIED QUESTION: What constitutes significant testing capacity when prioritizing EUA requests?
CLARIFIED ANSWER: FDA prioritizes EUA requests that significantly increase testing capacity, such as those reducing reliance on test supplies and enabling wide distribution to meet public health needs. Specific thresholds for high or low volume are not defined, but inquiries can be directed to the EUA mailbox with test details.
VERBATIM QUESTION: What constitutes significant testing capacity when prioritizing EUA requests?
VERBATIM ANSWER: We do prioritize review of EUA requests where authorization would significantly increase testing capacity such as tests that reduce reliance on test supplies and try to report widely distributed tests to address public health needs. We can't unfortunately provide specific numbers of what we consider to be high or low volume or throughput. But if you need help determining whether your test would be considered high testing capacity we recommend that you reach out through the EUA mailbox with information about the features of your test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA prioritization, Testing capacity, Lateral flow tests
REVIEW FLAG: False

QA Block 15-4
CLARIFIED QUESTION: For home collection kits, does the FDA require the review of shipping stability studies prior to EUA authorization?
CLARIFIED ANSWER: The FDA requires the review of shipping stability studies prior to EUA authorization for home collection kits. In certain cases, such as using an already authorized collection system, a right of reference may apply. Proprietary devices require repeated studies.
VERBATIM QUESTION: For home collection kits, does the FDA require the review of shipping stability studies prior to EUA authorization?
VERBATIM ANSWER: So for a home collection situation we are asking to review that shipping stability study prior to authorization. If you were already using something for which we have authorized and managed for a right of reference such as the Gates collection study. You could potentially if you use the sort of exact same things you can potentially fall under that right of reference that gates has offered and you can ask about that in the submission. But if you have a specifically proprietary unique device then those stability studies would need to be repeated.
SPEAKER QUESTION: Annie Wright
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Home collection kits, Shipping stability, EUA requirements
REVIEW FLAG: False

QA Block 15-7
CLARIFIED QUESTION: What are the stability data requirements for collection kits intended for professional use or point-of-care settings?
CLARIFIED ANSWER: For professional use or point-of-care settings, kits making claims for SARS or SARS panels are treated as devices, requiring shipping stability data. Proprietary collection devices require specific data, while widely used standard devices like nasal swabs may not need additional data.
VERBATIM QUESTION: What are the stability data requirements for collection kits intended for professional use or point-of-care settings?
VERBATIM ANSWER: So for professional use these are collection kits. Toby, you can help me out here. But if a kit makes a claim about use of the collection kit in for SARS or SARS plus a panel we would treat that as a device and we would ask for and obviously to be shipped and so we would look at the same sort of things there. Toby, did I get that right? Right. If it's some, you know, proprietary collection device we would expect to see information on the specific collection device including some of the stability data if you are, you know, simply using previously, you know, widely marketed, you know, a standard nasal swab and things like that then we are not likely to have additional questions.
SPEAKER QUESTION: Annie Wright
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Stability data for collection kits, Professional use requirements
REVIEW FLAG: False

QA Block 16-2
CLARIFIED QUESTION: Is there an upper age limit for individuals included in the intended use population for OTC designation?
CLARIFIED ANSWER: The FDA does not impose an upper age limit for the OTC designation. They recommend including individuals aged 65 and older in studies to ensure adequate representation across all age groups.
VERBATIM QUESTION: Is there an upper age limit for individuals included in the intended use population for OTC designation?
VERBATIM ANSWER: Yes. And then above 14 to above 65, you know, we would like to see, you know, obviously there is different potential issues in some groups so I would to see a good range so, you know, include those who are 65 plus and typically, you know, those we enrolled in age 14 to 65 is in typically depending on how many enrollees you have in your study you are going to see a good range on that. But make sure you have got representatives of those below 14 and those above 65 and then probably have plenty between the two.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: OTC population age range, upper age limit, clinical study design
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2025-01-03 10:58:22 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 17
##### Explicit Questions Extraction
QE 1-1: Is pooling considered screening or surveillance when collecting a ten-swab pool where all the swabs are placed into the same transport tube with media and specimens are recollected for individual results?
QE 1-2: Can you send questions about surveillance by email for specific feedback?
QE 1-3: What are the recommendations for validating asymptomatic screenings when there is already an EUA for the qualitative detection of SARS-CoV-2?
QE 1-4: Do you need additional pre-authorization data for a serial screening claim outlined in the supplemental EUA template?
QE 1-5: What data should be submitted for a supplemental EUA request including serial testing intervals and post-authorization validation studies?
QE 1-6: Is the serial testing approach acceptable for antigen assays that do not reach 80% sensitivity in symptomatic individuals?
QE 1-7: Should clinical evaluations in asymptomatic populations be completed prior to authorization for screening claims of tests with sensitivity below 80%?

##### Implicit Questions Extraction
QI 1-1: What are the details required for the FDA to distinguish between a screening versus surveillance testing proposal?
QI 1-2: Under what circumstances is pooling considered screening rather than surveillance?
QI 1-3: What recommendations does the FDA have for developers submitting supplemental EUA requests for serial testing claims?
QI 1-4: If a diagnostic test does not meet 80% sensitivity in symptomatic individuals, what are the requirements for FDA authorization of serial testing based on asymptomatic evaluations?
QI 1-5: Can serial testing be used for symptomatic individuals if an antigen test does not meet 80% sensitivity thresholds?
QI 1-6: Are there specific details or formats required for pre-submission emails regarding surveillance testing?

#### Section 2 of 17
##### Explicit Questions Extraction
QE 2-1: What is the process for submitting data to OIR for an EUA?
QE 2-2: For an OTC antigen test, is it necessary for the data to show a minimum of 80% agreement with a predicate to be considered for EUA approval?
QE 2-3: What PPA do you recommend for OTC antigen tests in the non-lab template compared to the comparator test?
QE 2-4: What PPA do you recommend for serial testing claims in the new supplemental template issued last week?
QE 2-5: Are the recommended PPAs for antigen tests applicable to symptomatic individuals?
QE 2-6: What are the requirements for the comparator test when used in EUA evaluations?

##### Implicit Questions Extraction
QI 2-1: What is the significance of the templates provided on the FDA website for EUA requests?
QI 2-2: What steps does the FDA take after receiving an EUA request from a developer?
QI 2-3: Is a predicate test needed for EUA submissions, and how does the comparator test differ in this context?
QI 2-4: What are the FDA's recommendations for minimum PPA for over-the-counter (OTC) antigen tests evaluated using the non-lab template?
QI 2-5: Are molecular tests with EUA authorization and high sensitivity an acceptable choice as comparator tests?
QI 2-6: What qualifies a molecular test for use as a comparator based on its sensitivity and method of operation (e.g., extraction step)?

#### Section 3 of 17
##### Explicit Questions Extraction
QE 3-1: Is the BioFire test the only one that can be used as a predicate for subsequent submissions by other manufacturers?

##### Implicit Questions Extraction
QI 3-1: What is the appropriate comparator for a clinical evaluation when submitting a 510k for a COVID-19 diagnostic test?
QI 3-2: Can an EUA-authorized RT-PCR assay be used as a comparator for EUA requests?
QI 3-3: How should developers intending to pursue the 510k pathway approach validation strategies and comparator methods?
QI 3-4: Are initial serology or antigen test applications required to go through the de novo pathway?

#### Section 4 of 17
##### Explicit Questions Extraction
QE 4-1: Does an EUA request under review for a similar expanded respiratory panel RSV and SARS-CoV-2 need to perform clinical studies this year given the low influenza prevalence?
QE 4-2: Would the expanded respiratory panel EUAs be able to remain in place despite low influenza prevalence?
QE 4-3: Is FDA open to the use of archived specimens to pursue clearance of an extended respiratory panel including flu A, flu B, RSV A&B, and SARS-CoV-2?

##### Implicit Questions Extraction
QI 4-1: Does the BioFire de novo authorization affect the EUA status of other developers' tests?
QI 4-2: Will EUAs for non-identical tests to BioFire remain valid despite the transition of BioFire's test to a de novo authorization?
QI 4-3: What options does the FDA provide for developers if viruses like influenza and RSV are at low prevalence during clinical studies?
QI 4-4: What are the expectations for archived sample selection regarding viral load or CT value representation for EUA submissions?
QI 4-5: What conditions of authorization apply to tests likely to be used in patients with general respiratory symptoms in lieu of an FDA-cleared respiratory panel?
QI 4-6: Does the FDA require a post-authorization prospective clinical study involving multiple sites for initially authorized multi-analyte respiratory panels?
QI 4-7: For a full EUA to traditional authorization conversion, what specific data requirements need to be submitted if using archived samples?
QI 4-8: How should developers handle the inclusion of viruses at low circulation in clinical studies due to pandemic conditions?

#### Section 5 of 17
##### Explicit Questions Extraction
QE 5-1: What are the differences in EUA requirements between prescription use lateral flow antigen tests and non-prescription use lateral flow antigen tests?
QE 5-2: For tests intended for lay users, what usability data should be submitted?
QE 5-3: For OTC tests where lay users receive and interpret results, what user comprehension data is expected?
QE 5-4: Can data from asymptomatic individuals for an OTC claim be collected post-authorization?
QE 5-5: What are the conditions under which a serial screening claim can be authorized with post-authorization data collection for asymptomatic individuals?
QE 5-6: What throughput or capacity qualifies a test as high or low volume in the context of EUA reviews?
QE 5-7: How can developers determine if their test would be considered high testing capacity for EUA review?

##### Implicit Questions Extraction
QI 5-1: What are the recommended analytical and clinical validation procedures for point-of-care settings?
QI 5-2: What criteria determine the appropriate settings for clinical evaluations?
QI 5-3: How can a developer validate a test for asymptomatic screening claims?
QI 5-4: What are the FDA's expectations for serial screening validation based on symptomatic use?
QI 5-5: Does the FDA consider usability and user comprehension data mandatory for OTC tests?
QI 5-6: What performance requirements must be met for serial screening claims to use post-authorization asymptomatic data collection?
QI 5-7: What constitutes significant testing capacity when prioritizing EUA requests?
QI 5-8: How should developers submit information about their test features for consideration as a high-capacity testing option?
QI 5-9: Why are lateral flow tests prioritized in point-of-care or home settings instead of high-throughput laboratory use?

#### Section 6 of 17
##### Explicit Questions Extraction
QE 6-1: Are over-the-counter COVID-19 test kits required to report results to public health authorities?

##### Implicit Questions Extraction
QI 6-1: Does the FDA have specific recommendations on mechanisms for reporting home test results to public health authorities?
QI 6-2: Under what circumstances is the development of a reporting mechanism included as a condition of authorization for a home COVID-19 test?
QI 6-3: How much time after authorization is typically allowed for developers to implement reporting mechanisms for home tests?
QI 6-4: What methods does the FDA consider effective for streamlining the reporting of data from COVID-19 tests?
QI 6-5: What types of advances in reporting mechanisms have been made by the HHS administration?
QI 6-6: Where can developers find announcements or updates from HHS on the availability of reporting features for COVID-19 tests?

#### Section 7 of 17
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 7-1: Why does the FDA believe external controls are important for quality control and training in COVID-19 home tests?
QI 7-2: What is the FDA's rationale for not typically requiring external controls for at-home tests?
QI 7-3: What specific characteristics should internal controls in at-home tests have to ensure valid results?
QI 7-4: Are there scenarios where external controls might still be recommended or required for at-home tests?
QI 7-5: What is the process for a developer to include an internal control in their at-home test submission?

#### Section 8 of 17
##### Explicit Questions Extraction
QE 8-1: What is the consideration for qualifying as high throughput when using 96 well plates read simultaneously compared to automated 384 well plates?
QE 8-2: If the throughput of the manual process meets or exceeds the throughput of the automated system, should automation be included in the EUA or should a separate EUA be submitted?
QE 8-3: If 96 well plates are used, but the throughput meets or exceeds the level of automation with 384 well plates, how would it be considered for qualification?

##### Implicit Questions Extraction
QI 8-1: What are the criteria for determining if a system qualifies as high throughput for EUA priority review?
QI 8-2: Is there a guidance document that specifies 384 well plates are necessary for high throughput classification?
QI 8-3: Does the FDA consider manual handling equivalence to automation when determining high throughput status?
QI 8-4: What steps should developers take if their test is no longer under active EUA review due to not meeting high throughput classification?
QI 8-5: Can the FDA provide test-specific guidance for modifications to meet high throughput criteria?

#### Section 9 of 17
##### Explicit Questions Extraction
QE 9-1: Is it possible to use an EUA authorized serology test as a comparator rather than an RT-PCR test for the clinical agreement study?
QE 9-2: Is there any rationale in requiring only RT-PCR tests as a comparator in the serology template?

##### Implicit Questions Extraction
QI 9-1: Why does the FDA recommend RT-PCR tests with an extraction step as the best comparator in clinical agreement studies?
QI 9-2: Can alternative comparator strategies, such as EUA-authorized serology tests, be submitted for FDA feedback through a pre-EUA?
QI 9-3: What is the process for submitting a pre-EUA for a non-recommended validation pathway?

#### Section 10 of 17
##### Explicit Questions Extraction
QE 10-1: Would a serology assay that looks at the spike protein potentially be a candidate for vaccine response?
QE 10-2: Was it just that particular issue or situation regarding serology tests that were not candidates, and not a blanket statement about all serology tests?

##### Implicit Questions Extraction
QI 10-1: What are the FDA's expectations for clinical studies to demonstrate claims about detecting specific immune responses to vaccines?
QI 10-2: How does the FDA recommend addressing theoretical mis-matches between vaccine antigens and authorized serology tests?
QI 10-3: What is the appropriate process for submitting a pre-EUA related to vaccine-specific serology tests?
QI 10-4: What additional details can test developers expect in future FDA communications on serology tests and vaccines?

#### Section 11 of 17
##### Explicit Questions Extraction
QE 11-1: Is the BioFire de novo now the predicate for all COVID NAT tests or only for multi-plex respiratory panel type NAT tests that include COVID?

##### Implicit Questions Extraction
QI 11-1: Can the BioFire predicate be used as a comparator for both emergency use authorization (EUA) and full regulatory submissions?
QI 11-2: What should test developers do if fully authorized tests are not readily available for comparison?
QI 11-3: Are high sensitivity RT-PCR tests acceptable as comparators for EUA submissions before more fully authorized predicates are available?
QI 11-4: What is the process for listing the BioFire test as a predicate in a 510k submission?

#### Section 12 of 17
##### Explicit Questions Extraction
QE 12-1: Does the FDA have standard criteria for PPA and NPA specifically for molecular tests in the asymptomatic post-authorization clinical study?

##### Implicit Questions Extraction
QI 12-1: Does the FDA have any data on the effectiveness of weekly serial testing programs with molecular tests in asymptomatic populations?
QI 12-2: Are there differences in expected performance standards for serial testing between molecular and antigen tests?
QI 12-3: What threshold does the FDA expect for asymptomatic screening performance in the absence of a pre-set standard?
QI 12-4: Does the FDA plan to set specific performance recommendations for serial testing in asymptomatic populations as more data becomes available?

#### Section 13 of 17
##### Explicit Questions Extraction
QE 13-1: Would the preference be to remove the vaccination exclusion for all subjects or just individuals over the age of 65?
QE 13-2: What type of test is this?

##### Implicit Questions Extraction
QI 13-1: What additional details should be included in the proposal when seeking feedback on a clinical trial for a molecular non-lab test?
QI 13-2: Is the FDA planning to provide further clarification on preferences about vaccination exclusions in future Town Hall meetings?

#### Section 14 of 17
##### Explicit Questions Extraction
QE 14-1: Is it okay to use inactivated virus of influenza A and B to make a contrived sample for the validation of a multiplex test for COVID and influenza?

##### Implicit Questions Extraction
QI 14-1: What should developers do if archived clinical samples for influenza A and B are unavailable?
QI 14-2: Is it permitted to proceed with a prospective study as part of the validation process for multiplex EUA authorization tests?
QI 14-3: Can developers submit a pre-EUA email explaining challenges in obtaining clinical samples for FDA consideration?
QI 14-4: Are there alternative pathways for validation if influenza A and B sample banks are depleted?
QI 14-5: What is the FDA's position on using contrived samples for non-SARS respiratory viruses in tests with new EUA applications?

#### Section 15 of 17
##### Explicit Questions Extraction
QE 15-1: For an EUA submission, does the FDA require a simulated 'worst-case shake and bake' scenario for shipping and handling stability testing?
QE 15-2: Is it acceptable to submit shipping studies that only show the transportation stability of the device without simulated 'shaking and baking'?
QE 15-3: For extreme temperatures, does the FDA expect such data to be included in the EUA submission, or can it be submitted later as part of an ongoing study?
QE 15-4: For home collection kits, does the FDA require the review of shipping stability studies prior to EUA authorization?
QE 15-5: If using a previously authorized collection method, can a submission fall under the right of reference, or does stability testing need to be repeated for proprietary unique devices?
QE 15-6: Can real-time stability data be submitted post-EUA authorization, or is pre-authorization accelerated stability data mandatory for collection kits?
QE 15-7: What are the stability data requirements for collection kits intended for professional use or point-of-care settings?
QE 15-8: If a collection kit uses widely marketed standard devices, like a nasal swab, does it still need specific stability data to be provided?

##### Implicit Questions Extraction
QI 15-1: What types of stability testing are considered sufficient for EUA authorization of a COVID-19 diagnostic collection kit?
QI 15-2: Does the FDA require stability testing data for the approval of home collection kits on return shipping conditions?
QI 15-3: What are the FDA's expectations for documenting the expiration date for home collection devices during EUA authorization?
QI 15-4: What are the requirements for real-time stability testing versus accelerated stability testing for collection kits?
QI 15-5: Does the FDA require additional stability data for proprietary collection devices compared to standard, widely marketed devices?
QI 15-6: If a collection kit is intended to support both SARS and SARS plus a panel, will it be treated as a higher regulatory burden device under EUA?

#### Section 16 of 17
##### Explicit Questions Extraction
QE 16-1: Can you confirm that the age range for an OTC designation is 2 to 65 years, or is 3 to 65 years adequate?
QE 16-2: Is there an upper age limit for individuals included in the intended use population for OTC designation?

##### Implicit Questions Extraction
QI 16-1: Are there specific data requirements for the self-collection age group of 14 and above?
QI 16-2: What are the considerations for including age groups over 65 in study populations?
QI 16-3: How should developers ensure a representative distribution of study subjects across all age groups?
QI 16-4: Are there guidelines for parent or guardian sample collection for children under 14?

#### Section 17 of 17
##### Explicit Questions Extraction
QE 17-1: Is the performance evaluation, specifically the emerging viral mutation monitoring plan, expected for manufacturers who already have an EUA?
QE 17-2: Can you share examples of how manufacturers address monitoring and dealing with new and emerging viral mutations for serology or neutralizing antibody tests?

##### Implicit Questions Extraction
QI 17-1: What specific elements should be included in a monitoring plan for emerging viral mutations?
QI 17-2: For newly submitted assays, what level of detail does the FDA expect developers to include regarding mutation monitoring?
QI 17-3: How can molecular test developers determine if viral mutations will affect primer or probe performance through modeling?
QI 17-4: What are the FDA's expectations for developers regarding the sequence analysis for SARS-CoV-2 in serology tests?
QI 17-5: What information should antigen test developers provide about antibodies used in their tests?
QI 17-6: How should polyclonal antibody developers account for antigen sequences in their monitoring plans?
QI 17-7: What resources or tools does the FDA recommend for examining US circulating sequence databases?
